Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Apr 6th, 2026

LECO_Weekly-Healthcare-News_4-6-2026Download

Healthcare Weekly News and Deals – April 6th, 2026

  1. Anthropic, backed by a $30 billion Series G, acquires stealth startup Coefficient Bio in a $400 million all-stock AI-biotech deal. AI leader Anthropic has acquired Coefficient Bio, a stealth-mode startup specializing in AI for biological research, in a transaction valued at approximately $400 million in stock. Coefficient Bio, founded just eight months ago by elite researchers from Genentech’s Prescient Design unit, was backed by the venture firm Dimension, which reportedly held a 50% stake in the company. The acquisition marks a significant vertical expansion for Anthropic, as the Coefficient team—including co-founders Nathan C. Frey and Samuel Stanton—will join its Healthcare and Life Sciences division. The deal aims to transform the Claude AI model into a specialized infrastructure for drug discovery and biopharma workflows, positioning Anthropic to compete directly with specialized AI-medicine firms in a market estimated to be worth over $100 B. (Link)
  2. Merit Medical (NASD: MMSI) strengthens oncology division with the strategic acquisition of Viewpoint Medical. Merit Medical (MMSI) has finalized its purchase of View Point Medical to expand its therapeutic oncology portfolio. The acquisition includes View Point’s steerable needle technology, which is critical for accessing difficult-to-reach tumors during biopsy and ablation procedures. This strategic tuck-in acquisition allows Merit to offer a more comprehensive suite of tools to interventional radiologists. Investors view this move as a way for Merit to maintain its growth trajectory in the high-value oncology market while utilizing its established sales force to drive rapid adoption of the new technology across global hospitals. (Link)
  3. Blackstone-backed AGS Health said to file for $500 million India IPO to capitalize on healthcare outsourcing demand. AGS Health, a leading provider of revenue cycle management services backed by private equity giant Blackstone, is reportedly filing for an Initial Public Offering (IPO) in India to raise approximately $500 million. This move allows Blackstone to partially exit its investment while providing AGS Health with the capital necessary to scale its technology-enabled services and global delivery model. The IPO highlights the robust investor appetite for healthcare IT outsourcing firms that utilize AI and automation to streamline clinical documentation and billing. By listing on the Indian exchanges, AGS Health aims to leverage its significant operational footprint in the region to attract both domestic and international institutional investors. (Link)
  4. Eli Lilly (NYSE: LLY) acquires Centessa Pharmaceuticals for $1.5 billion to advance sleep disorder treatments. Eli Lilly (LLY) has reached an agreement to acquire Centessa Pharmaceuticals in a deal valued at approximately $1.5 billion. The acquisition focuses on Centessa’s promising pipeline of orexin receptor agonists, which are being developed to treat narcolepsy and other sleep disorders. Lilly aims to leverage its global R&D infrastructure to accelerate these therapies through clinical trials. The deal reinforces Lilly’s commitment to expanding its neuroscience portfolio beyond Alzheimer’s and pain management. By acquiring Centessa, Lilly gains access to potentially best-in-class molecules that address a significant unmet need in the sleep medicine market. (Link)
  5. Quantum Health acquires CirrusMD while GE HealthCare (NASD: GEHC) completes acquisition of Intelerad. These deals highlight a massive shift toward integrated digital health ecosystems where navigation, virtual delivery, and diagnostic data management are seamlessly combined to improve patient outcomes and provider efficiency. (Link)
  6. Grovecourt Capital Partners portfolio company Premier Radiology Services acquires Global Imaging Solutions to bolster teleradiology subspecialty expertise. Premier Radiology Services has expanded its domestic footprint by acquiring Global Imaging Solutions. This deal, backed by Grovecourt Capital Partners, focuses on increasing the volume of subspecialty interpretations, such as musculoskeletal and neuroradiology, available to its clients. The acquisition comes at a time when the demand for remote diagnostic services is surging due to radiologist shortages. Premier Radiology aims to use this merger to provide faster turnaround times and higher-quality reports to rural hospitals and imaging centers that lack on-site specialists, reinforcing its position as a leading teleradiology provider. (Link)
  7. Office Ally, backed by Barings, Francisco Partners, and New Mountain Capital, acquires Jopari Solutions to scale electronic transaction processing. The acquisition expands Office Ally’s clearinghouse network by integrating Jopari’s capabilities in electronic billing, clinical attachments, and payment workflows. Together, the combined platform enhances interoperability and supports higher transaction volumes across provider and payer interactions. The deal strengthens Office Ally’s position in end-to-end healthcare transaction infrastructure. It also reflects a broader shift toward automation and streamlined administrative operations across the healthcare system. (Link)
  8. Jukebox Health acquires Braided Health to enhance AI-driven integrated care platforms for high-needs dual-eligible populations. Jukebox Health acquired Braided Health to expand its AI-driven integrated care platform for high-need, dual-eligible Medicare and Medicaid populations. The transaction combines Braided Health’s AI-powered care management technology with Jukebox’s in-home clinical services, enabling health plans to better identify risks and intervene earlier. By integrating care management workflows with real-time, in-home clinical insights, the platform aims to improve outcomes while reducing total cost of care for complex patient populations. (Link) 
  9. Community Health Systems (NYSE: CYH) completes divestiture of Huntsville-based Crestwood Medical Center. The transaction combines Braided Health’s AI-powered care management technology with Jukebox’s in-home clinical services, enabling health plans to better identify risks and intervene earlier. By integrating care management workflows with real-time, in-home clinical insights, the platform aims to improve outcomes while reducing total cost of care for complex patient populations. The combined platform strengthens Jukebox’s ability to serve dual-eligible Medicare and Medicaid populations at scale. The deal reflects a broader push to modernize legacy care management systems through data-driven, home-based interventions. (Link)
  10. Virtual care platform OpenLoop Health acquires nutrition-focused startup Season Health to expand clinical service offerings. The acquisition adds Season Health’s nutrition therapy capabilities to OpenLoop’s telehealth infrastructure, enabling more comprehensive care across chronic conditions and weight management programs. OpenLoop, which supports a range of virtual care providers including GLP-1 platforms, can now integrate dietitian-led services directly into its clinical workflows. The deal strengthens its ability to offer more complete, end-to-end virtual care solutions. It also reflects a broader trend of telehealth platforms expanding into lifestyle-based interventions to improve patient outcomes. (Link)
  11. Sentinel Capital Partners portfolio company Catalyst MedTech acquires X3D to expand advanced imaging service capabilities. Catalyst MedTech, formerly known as TTG Imaging Solutions and a portfolio company of Sentinel Capital Partners, has acquired X3D. This acquisition enhances Catalyst MedTech’s portfolio of diagnostic imaging services, particularly in the realm of specialized 3D imaging technology and maintenance. Sentinel Capital continues to support Catalyst’s aggressive buy-and-build strategy to create a dominant national player in the refurbished medical equipment and imaging service market. The integration of X3D is expected to provide Catalyst with deeper technical expertise and a broader customer base among hospitals and independent diagnostic centers.(Link)
  12. Gyde acquires Avid Health to launch AI-enabled Medicare brokerage platform and expand market footprint. Gyde has successfully acquired Avid Health, marking the launch of a new AI-enabled brokerage platform specifically designed for the Medicare market. The acquisition combines Gyde’s technology with Avid Health’s distribution network to streamline the plan selection process for seniors. By utilizing AI to analyze patient data and plan benefits, the new platform aims to increase transparency and match beneficiaries with optimal coverage. This deal reflects the increasing application of automation and artificial intelligence in the insurance brokerage space to simplify complex regulatory environments and improve consumer decision-making.(Link)
  13. LongueVue Capital and Swaney Group Capital partner to invest in Apex Dental Laboratory Group to drive regional expansion. Private equity firm LongueVue Capital has partnered with Swaney Group Capital to make a significant growth investment in Apex Dental Laboratory Group. Apex is a leading provider of dental lab services, and this capital infusion is intended to support the company’s buy-and-build strategy across the United States. The investors aim to leverage Apex’s digital dentistry capabilities to consolidate a fragmented market of local dental labs. This investment highlights the continued interest of PE firms in the dental services organization (DSO) and ancillary dental technology sectors, focusing on operational scaling through technology.(Link)
  14. Vision Innovation Partners acquires Frederick Eye Institute to expand ophthalmic surgical platform in the Mid-Atlantic. Vision Innovation Partners, a leading ophthalmic platform, has acquired Frederick Eye Institute, a multi-specialty ophthalmology practice. This acquisition further solidifies Vision Innovation Partners’ presence in the Mid-Atlantic region, adding significant clinical and surgical capacity. The firm continues to pursue a consolidation strategy, acquiring high-quality practices to provide integrated eye care services ranging from routine exams to complex surgeries. By joining the platform, Frederick Eye Institute will benefit from enhanced administrative support and access to advanced diagnostic technology, reflecting the ongoing private equity-led consolidation trend within the ophthalmology sector.(Link)

Venture Deals and Other

  1. WHOOP raises $575 million in Series G funding at a $10.1 billion valuation to scale its wearable health platform. The round includes participation from high-profile athletes and celebrities such as LeBron James, Cristiano Ronaldo, Rory McIlroy, and Shane Lowry, alongside institutional investors including Collaborative Fund, Mayo Clinic, Mubadala Investment Company, and Qatar Investment Authority. The capital will support expansion of its subscription-based wearable platform focused on sleep, recovery, and performance, while accelerating product development, enhancing data-driven health insights, and scaling its global membership base, with a continued push into broader health monitoring capabilities and long-term growth initiatives. (Link)
  2. Ambient Clinical Analytics raises $5 million and appoints Brian Tufts as CEO to scale AWARE clinical AI platform. Ambient Clinical Analytics has successfully closed a $5 million funding round aimed at scaling its AWARE platform, a clinical decision support tool designed to reduce medical errors in high-acuity settings like the ICU. Alongside the investment, the company named Brian Tufts as its new CEO to lead the commercial expansion. The funding will be used to integrate more advanced AI capabilities and expand the platform’s footprint in hospitals globally. Ambient’s technology focuses on real-time data visualization to help clinicians make faster, more accurate decisions, addressing the critical need for burnout reduction and improved patient safety. (Link)
  3. Jimini Health raises $17 million in venture funding to expand its AI-driven behavioral health platform. Jimini Health has secured $17 million in a new funding round to accelerate the growth of its AI-powered mental health platform. The investment will be directed toward expanding the company’s therapist network and enhancing its AI tools that assist in patient monitoring and personalized treatment planning. Jimini Health focuses on providing scalable, evidence-based behavioral care by combining human expertise with machine learning. This round reflects the continued venture capital appetite for AI solutions that address the global shortage of mental health professionals and provide more accessible care options for patients. (Link)
  4. Insight Health raises $11 million to scale clinical AI agents for automated healthcare administrative tasks. Insight Health has raised $11 million in venture capital to further develop and deploy its clinical AI agents. These agents are designed to automate routine administrative tasks for healthcare providers, such as documentation, scheduling, and billing queries. By offloading these burdens from clinical staff, Insight Health aims to reduce provider burnout and improve operational efficiency within hospital systems. The funding will support the expansion of the engineering team and the commercialization of the platform. This investment highlights the trend of “narrow AI” solving specific, high-friction problems in healthcare administration. (Link)
  5. Naver D2SF makes strategic investment in Soundable to advance AI-based respiratory health monitoring technology. Naver D2SF, the startup investment arm of South Korean tech giant Naver, has made a strategic investment in Soundable. Soundable specializes in AI-driven sound analysis technology that monitors respiratory health through cough and breathing patterns captured via smartphones. This investment is part of Naver’s broader strategy to expand its digital health ecosystem and integrate advanced diagnostic tools into its consumer platforms. The funds will help Soundable refine its algorithms and seek regulatory approvals in international markets. The deal underscores the rising interest in non-invasive, remote monitoring technologies that leverage everyday devices for health screening. (Link)
  6. Long Tail secures growth investment to expand its technology-driven healthcare solutions and market reach. Long Tail has announced a new growth investment aimed at scaling its technology platform. While the specific dollar amount was not disclosed, the funding will be used to enhance the company’s product development and expand its sales and marketing efforts. Long Tail focuses on providing specialized software solutions that help healthcare organizations manage “long tail” data and niche operational challenges. This investment reflects a growing interest from venture and growth equity firms in specialized SaaS platforms that address specific inefficiencies within the healthcare value chain, rather than broad, general-purpose software. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Mar 30th, 2026

LECO_Weekly-Healthcare-News_3-30-2026Download
  1. Abbott (NYSE: ABT) Completes Acquisition of Exact Sciences (NASDAQ: EXAS) Abbott (NYSE: ABT) has officially finalized its acquisition of Exact Sciences (NASDAQ: EXAS), a move aimed at bolstering its leadership in the cancer diagnostics and screening market. The integration of Exact Sciences’ flagship Cologuard technology into Abbott’s massive global diagnostics portfolio is expected to drive significant revenue growth and expand access to non-invasive screening tools. Investors are monitoring how this multibillion-dollar deal will impact Abbott’s long-term earnings per share. This strategic consolidation highlights the ongoing trend of medical device giants acquiring specialized biotech innovators to maintain a competitive edge in the preventive healthcare sector. (Link)
  2. Merck (NYSE: MRK) to Acquire Terns Pharmaceuticals (NASDAQ: TERN) for $53 Per Share in Cash Merck (NYSE: MRK) has entered into a definitive agreement to acquire Terns Pharmaceuticals (NASDAQ: TERN) for $53 per share in an all-cash transaction. This acquisition allows Merck to gain control of Terns’ promising pipeline of oncology and metabolic disease treatments, specifically focusing on small-molecule oral therapies. The premium price reflects investor confidence in Terns’ clinical data and the potential for these assets to offset upcoming patent expirations in Merck’s existing portfolio. The deal reinforces Merck’s aggressive M&A strategy to diversify its pipeline through high-value biotech acquisitions that offer immediate technological advantages and long-term market exclusivity. (Link)
  3. Infosys (NYSE: INFY) to Acquire US Firms Optimum Healthcare IT for $465 Million and Stratus for $95 Million Infosys (NYSE: INFY) is significantly expanding its footprint in the United States healthcare sector by acquiring Optimum Healthcare IT for $465 million and Stratus for $95 million. These investments are designed to enhance Infosys’ digital transformation capabilities, specifically within healthcare provider networks and cloud-based medical data management. By bringing these specialized consulting firms under the Infosys umbrella, the company aims to offer more robust, end-to-end IT solutions to American healthcare systems. Investors view this as a strategic deployment of capital to capture the growing demand for digital modernization and data interoperability within the heavily regulated healthcare industry. (Link)
  4. Cencora (NYSE: COR) to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners’ Retina Business Cencora (NYSE: COR), formerly AmerisourceBergen, has announced a deal to acquire the retina-specific business of EyeSouth Partners to expand its Retina Consultants of America (RCA) platform. EyeSouth Partners is backed by Olympus Partners. This acquisition underscores Cencora’s commitment to specialized physician services, particularly in the high-growth ophthalmology sector. By integrating these practices, Cencora enhances its scale in clinical research and specialty distribution, providing a more comprehensive value proposition to manufacturers and patients alike. The investment reflects a broader private equity-style roll-up strategy within the specialty care market, aimed at optimizing operational efficiencies and expanding the company’s geographic reach across the United States. (Link)
  5. Efferent Acquired by Hopper OS via Financial Sponsor GPI Capital Through an LBO Efferent was acquired by Hopper OS on March 24, 2026, through a leveraged buyout (LBO) backed by financial sponsor GPI Capital. This acquisition is intended to integrate Efferent’s specialized technology into Hopper OS’s “intelligent healthcare operating system,” creating a more seamless data environment for providers. GPI Capital’s involvement indicates a strong private equity interest in the healthcare infrastructure space, focusing on companies that can automate clinical workflows. The undisclosed investment will facilitate the scaling of Efferent’s tools, allowing Hopper OS to offer a more robust, AI-enhanced suite of products to its global healthcare clientele. (Link)
  6. HealthTech Solutions Acquired by Health Management Associates via Financial Sponsor BPOC Through an LBO Health Management Associates (HMA) has completed the acquisition of HealthTech Solutions through a leveraged buyout supported by financial sponsor BPOC. The deal, finalized on March 27, 2026, aims to merge HMA’s Medicaid expertise with HealthTech’s advanced technological capabilities. BPOC’s investment highlights the private equity sector’s focus on Medicaid modernization and state-level healthcare IT. By acquiring HealthTech, HMA strengthens its ability to provide technical advisory services to government agencies. The undisclosed transaction is expected to drive growth by enabling HMA to manage complex data systems and improve health outcomes for vulnerable populations through better technology. (Link)
  7. Careflow Receives Growth Investment from Blueprint Equity to Expand Product Platform Careflow has secured an undisclosed amount of development capital from Blueprint Equity as of March 26, 2026. This strategic growth investment is earmarked for the expansion of Careflow’s product platform and the acceleration of its market penetration. Blueprint Equity’s participation marks a significant vote of confidence in Careflow’s software solutions for the healthcare industry. The capital infusion will allow the company to scale its operations and enhance its technological offerings, focusing on improving workflow efficiency for healthcare professionals. This deal exemplifies the active role of private equity in fostering the growth of mid-sized health-tech firms aiming for market leadership. (Link)
  8. Novartis to Acquire Excellergy in Up to $2B Deal to Expand Allergy Pipeline Novartis has agreed to acquire Excellergy, a U.S.-based biotech developing next-generation therapies for allergic diseases, in a deal worth up to $2 billion including milestone payments. The acquisition adds Excellergy’s lead asset, Exl-111, a next-generation anti-IgE antibody currently in early-stage clinical development, designed to deliver faster and more durable suppression of allergic responses. Exl-111 builds on the same biological pathway as Novartis’ blockbuster Xolair but is engineered to improve efficacy, dosing convenience, and overall disease control across multiple IgE-mediated conditions. The transaction is expected to close in the second half of 2026, pending regulatory approvals, further strengthening Novartis’ leadership in immunology and allergy therapeutics. (Link)
  9. PCSI Completes Acquisition of CareStarter and Feedback to Launch PCSIx Innovation Unit PCSI has finalized the acquisition of CareStarter and Feedback, two companies focused on patient engagement and care coordination. These acquisitions serve as the foundation for PCSI’s new innovation unit, PCSIx. The investment aims to bridge the gap between healthcare providers and patients by utilizing CareStarter’s resource platforms and Feedback’s communication tools. By consolidating these technologies, PCSI intends to streamline the patient journey and improve health literacy. This move signals a shift toward integrated, patient-centered care models, with the investor focusing on long-term value through improved patient outcomes and reduced administrative friction in the care delivery process. (Link)
  10. Collectly to Acquire Pledge Health to Accelerate AI Automation in Patient Finance Collectly has announced its acquisition of Pledge Health, a strategic move designed to integrate AI-driven automation into the patient financial experience. The acquisition focuses on streamlining medical billing and transparent pricing, addressing one of the most significant pain points in American healthcare. By combining forces, Collectly and Pledge Health aim to provide patients with clearer financial insights while helping providers increase collection rates through automated workflows. This investment highlights the growing market for fintech solutions within the healthcare sector, where AI is being leveraged to reduce manual errors and improve the overall transparency of healthcare costs. (Link)
  11. Vitality Acquires Ramp Health to Merge AI Behavioral Health and Workplace Safety Vitality has successfully acquired Ramp Health, aiming to create a comprehensive platform that merges AI-powered behavioral health services with workplace safety protocols. This acquisition is part of Vitality’s broader strategy to enhance corporate wellness programs by providing employers with data-driven tools to support employee mental and physical health. The integration of Ramp Health’s expertise allows Vitality to offer more personalized health interventions and preventative safety measures. Investors see this as a timely move, given the increasing corporate focus on employee well-being and the role of AI in delivering scalable health solutions in a professional environment. (Link)
  12. Palm Primary Care Acquires Two Clinics in Azle to Expand Local Access Palm Primary Care has expanded its clinical footprint by acquiring two primary care clinics in Azle, Texas. This investment is part of the company’s localized growth strategy, focusing on increasing access to high-quality primary care in suburban and rural areas. By acquiring established practices, Palm Primary Care can immediately serve an existing patient base while implementing its standardized care models and advanced technology systems. The deal reflects a continuing trend of consolidation in the primary care sector, where larger organizations acquire independent practices to achieve economies of scale and provide more integrated services to the local community. (Link)
  13. HealthDrive Corp Acquires Georgia Long-Term Care Consulting HealthDrive Corp, backed by Cressey & Company, has acquired Georgia Long-Term Care Consulting, expanding its reach into the specialized field of post-acute and long-term care services. This acquisition allows HealthDrive to strengthen its consultancy and on-site clinical service offerings for seniors in long-term care facilities. The investment is driven by growing demand for specialized medical services within the aging population. By integrating the Georgia-based firm, HealthDrive enhances its ability to manage complex care needs and regulatory compliance for long-term care facilities. This move reinforces HealthDrive’s position as a major player in the evolving landscape of senior healthcare services in the United States. (Link)
  14. Cerebral Acquires Inflow to Broaden Mental Health and ADHD Support Cerebral has acquired Inflow, a startup focused on digital tools for ADHD management, to broaden its behavioral health platform. This acquisition enables Cerebral to provide more specialized, non-clinical support for neurodivergent individuals, complementing its existing telepsychiatry services. The investment highlights Cerebral’s strategy to become a holistic provider of mental health solutions by incorporating self-management tools and community support into its clinical model. Investors are watching how this expansion into digital therapeutics will help Cerebral differentiate itself in a crowded telehealth market while improving long-term patient engagement and clinical outcomes for those with ADHD. (Link)
  15. Gilead Sciences to Acquire Ouro Medicines in $2.2B Deal to Expand Autoimmune Pipeline Gilead Sciences announced it will acquire Ouro Medicines in a transaction valued at up to approximately $2.2 billion, including $1.675 billion upfront and potential milestone payments. The deal centers on Ouro’s lead asset, a clinical-stage BCMAxCD3 T-cell engager designed to treat severe autoimmune diseases by targeting pathogenic B cells. Early data has shown promising efficacy and a differentiated safety profile, positioning the therapy as a potential “immune reset” approach. Strategically, the acquisition expands Gilead’s inflammation and immunology pipeline as it seeks to diversify beyond its core HIV franchise. (Link)
  16. RTW Investments Boosts Stake in Cogent Biosciences RTW Investments increased its position in U.S.-based Cogent Biosciences by purchasing over 4.1 million shares, representing an estimated $116 million investment and signaling strong conviction in the company’s pipeline. The stake now accounts for roughly 2.7% of RTW’s reportable assets, highlighting the importance of the position within its biotech-focused portfolio. Cogent is advancing precision therapies for genetically defined diseases, with key U.S. regulatory milestones, including an FDA decision expected in late 2026, acting as major value inflection points. The move reflects continued investor interest in U.S. biotech innovation, particularly companies nearing potential commercialization. (Link)
  17. GeBBS Healthcare Solutions Announces Acquisition of RND OptimizAR GeBBS Healthcare Solutions, Inc., a leading provider of technology-enabled Revenue Cycle Management (RCM) and Risk Adjustment Solutions for healthcare providers and payers, announced this morning the acquisition of RND OptimizAR, an India-based specialized provider of Revenue Cycle Management services focused on the Durable Medical Equipment (DME) and Home Medical Equipment (HME) market. The deal strengthens GeBBS’ capabilities in niche RCM segments. GeBBS is backed by global investors including EQT and ChrysCapital. (Link)
  18. Vision Innovation Partners Acquires Frederick Eye Institute Vision Innovation Partners (VIP), a leading Mid-Atlantic eye care platform with 69 locations and backed by Gryphon Investors, announced this morning the acquisition of Frederick Eye Institute, a comprehensive ophthalmology practice in Frederick, Maryland. This marks VIP’s 28th add-on acquisition since 2017 and further strengthens its presence in the key Maryland. (Link)
  19. AI Maverick Intel Announces LOI to Acquire HEAL Access Canada  The proposed acquisition would integrate HEAL’s AI-powered patient navigation and virtual care coordination platform into its ecosystem. The deal represents the first transaction under its Right of First Refusal agreement with HEAL. (Link)
  20. Monument MicroCap Partners Invests in Champion Wellness Centers to Support Growth and Expansion The investment supports Champion Wellness Centers, a Tampa-based provider of chiropractic and multidisciplinary wellness services. The company operates a network of clinics offering physical therapy, regenerative medicine, and other integrated treatments, positioning it to benefit from growing demand for holistic care. The partnership will support geographic expansion and add-on acquisitions. (Link)

Venture Deals and Other

  1. eMed Raises $200 Million Led by Aon, Including Participation from Tom Brady and Linda Yaccarino to Expand GLP-1 Access eMed has received a strategic investment from a high-profile group including Tom Brady and Linda Yaccarino to support its mission of expanding access to GLP-1 weight-loss medications. The funding will enhance eMed’s digital health platform, which provides clinical oversight and testing for patients seeking metabolic treatments. This investment reflects the massive market demand for weight-loss drugs and the role of telehealth in managing prescription distribution. The involvement of such prominent figures suggests a shift toward celebrity-backed healthcare ventures that aim to combine medical credibility with mass-market consumer appeal in the rapidly growing obesity-treatment sector. (Link)
  2. Adonis Raises $40 Million in Series C Funding to Transform Revenue Cycle Management Adonis has successfully closed a $40 million Series C funding round to accelerate the development of its AI-driven revenue cycle management platform. This significant capital infusion will be used to enhance the company’s automation capabilities, helping healthcare providers reduce administrative burdens and improve billing accuracy. The investment round reflects strong venture capital confidence in Adonis’s ability to solve complex financial inefficiencies within the healthcare system. With this new funding, Adonis plans to expand its engineering team and scale its go-to-market strategies, aiming to become the standard for financial operations in large-scale medical groups and health systems. (Link)
  3. Blossom Health Secures Series A Funding Led by Headline to Expand Telepsychiatry Services Blossom Health has raised a Series A investment round, with Headline serving as the lead investor. The funding is intended to scale Blossom Health’s telehealth and telepsychiatry platform, which focuses on providing accessible mental healthcare to underserved populations. Headline’s involvement brings both capital and strategic expertise in scaling consumer-facing digital health brands. Blossom Health plans to use the funds to hire more clinical staff and enhance its mobile application interface. This deal highlights the continued venture capital appetite for mental health startups that leverage technology to overcome traditional barriers to care, such as cost and geographic location. (Link)
  4. Dimer Health Raises $13.5 Million for AI-Driven Post-Discharge Care Platform Dimer Health has secured $13.5 million in funding to support its AI-driven platform designed to improve post-discharge patient care. The investment will be used to further develop technology that monitors patients after they leave the hospital, aiming to reduce readmission rates and improve recovery outcomes. By utilizing predictive analytics, Dimer Health helps clinicians identify high-risk patients who may need immediate intervention. This venture deal underscores the growing interest in “hospital-at-home” models and the use of artificial intelligence to bridge the gap between acute hospital stays and long-term recovery in a home setting. (Link)
  5. Gimlet Labs Raises $80 Million to Transform AI Inference Infrastructure Gimlet Labs has closed a substantial $80 million funding round aimed at transforming AI inference infrastructure. While not strictly a healthcare firm, its technology is pivotal for the future of AI-driven medical diagnostics and drug discovery. The investment will allow Gimlet Labs to scale its hardware and software solutions that make running complex AI models faster and more cost-effective. Venture capitalists are betting on Gimlet Labs to provide the foundational infrastructure that will power the next generation of AI applications across various sectors. This capital will be used for research and development and expanding their manufacturing capabilities to meet global demand. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Mar 23rd, 2026

LECO_Weekly-Healthcare-News_3-23-2026Download
  1. GE HealthCare (NASD: GEHC) Completes $2.3B Acquisition of Intelerad to Bolster Cloud-First Imaging Solutions GE HealthCare (NASDAQ: GEHC) has finalized its acquisition of Intelerad Medical Systems, a leading provider of enterprise imaging software. This strategic move is designed to accelerate GE HealthCare’s transition toward cloud-based enterprise solutions and “precision care.” By integrating Intelerad’s informatics platform, GE HealthCare aims to improve clinician workflows and data accessibility across hospital systems. The acquisition enhances the company’s digital health portfolio, focusing on scalable, interoperable imaging tools that reduce administrative burdens. This deal reflects the broader industry trend of medical technology giants acquiring software firms to dominate the healthcare data infrastructure market. (Link)
  2. Movano (NASD: MOVE) Completes All-Stock Merger with Corvex (NASD: CVEX) and Rebrands Movano Health (NASDAQ: MOVE) and Corvex have completed a strategic merger, creating a unified entity focused on AI-driven cloud infrastructure for healthcare. Movano, known for its wearable medical technology and the Evie Ring, will leverage Corvex’s cloud capabilities to enhance its data analytics and patient monitoring services. The merger aims to create a “cloud infrastructure powerhouse” capable of processing large-scale health data for clinical and consumer applications. This transaction reflects the merging of hardware and software capabilities in the wearable tech space to provide more comprehensive, actionable health insights through artificial intelligence. (Link)
  3. Knowtion Health Acquires Revly to Enhance RCM and AI-Driven Denial Management Management via its financial sponsors Arsenal Capital Partners, Sunstone Partners and Ardan Equity Knowtion Health, a leader in revenue cycle management (RCM) and claim denial resolution, has acquired Revly, an AI-powered billing technology company. Knowtion Health is a portfolio company of Sunstone Partners. This acquisition integrates Revly’s advanced automation into Knowtion’s existing platforms to help hospitals and health systems recover unpaid claims more efficiently. By combining human expertise with Revly’s AI, Knowtion aims to reduce the rising rate of insurance denials. This deal underscores the high demand for AI-driven solutions in the administrative healthcare space to combat labor shortages and complex payer requirements. (Link)
  4. Prestige Consumer Healthcare (NYSE: PBH) to Acquire Breathe Right from Foundation Consumer Healthcare Prestige Consumer Healthcare Inc. (NYSE: PBH) has signed a definitive agreement to acquire the Breathe Right nasal strip brand from Foundation Consumer Healthcare. This acquisition strengthens Prestige’s portfolio of leading over-the-counter consumer brands, specifically within the respiratory care segment. Breathe Right is the global leader in the nasal strip category, and this move is expected to be immediately accretive to Prestige’s earnings and free cash flow. The deal highlights Prestige’s ongoing strategy of acquiring established, high-growth consumer health brands to leverage its existing retail distribution network and marketing infrastructure. (Link)
  5. Pacific Avenue Capital Partners Completes Acquisition of Care.com from IAC (NASD: IAC) An affiliate of Pacific Avenue Capital Partners has completed the acquisition of Care.com from IAC (NASDAQ: IAC). Care.com is the world’s leading platform for finding and managing high-quality family care, including childcare, senior care, and specialized medical care. Under the new ownership of Pacific Avenue, the company plans to invest in product innovation and expand its enterprise offerings for employers. This private equity buyout signifies a shift for Care.com as it moves away from a conglomerate structure to focus on independent growth in the rapidly expanding digital caregiving marketplace. (Link)
  6. Aria Care Partners Acquires Coronado Dental to Expand On-Site Clinical Services in Arizona via its financial sponsor Serent Capital Aria Care Partners, a leading provider of onsite ancillary medical services for skilled nursing facilities, has acquired Coronado Dental. This acquisition marks Aria’s entry into the Arizona market. Aria Care Partners, which is backed by private equity investment, focuses on delivering dental, vision, hearing, and podiatry services directly to residents in long-term care facilities. By acquiring Coronado Dental, Aria expands its footprint and reinforces its position as a dominant player in the specialized geriatric clinical services sector. The deal highlights the consolidation of fragmented ancillary care providers under larger, PE-backed management platforms. (Link)
  7. Blackstone-Backed (NYSE: BX) Chartis Acquires Health Tech Firm Leap AI The Chartis Group, a healthcare advisory and analytics firm backed by Blackstone (NYSE: BX), has acquired Leap AI. Leap AI specializes in healthcare-specific artificial intelligence automation, focusing on streamlining clinical and administrative workflows. This acquisition allows Chartis to integrate advanced AI capabilities into its consulting services, helping hospital systems improve operational efficiency. For Blackstone, this move represents a continued investment in “applied AI” within the healthcare sector, moving beyond general software into tools that solve specific provider pain points. The deal highlights the aggressive expansion of tech-enabled consulting platforms. (Link)
  8. WELL Health (TSX: WELL) Subsidiary WELLSTAR Acquires Two Billing Platforms to Expand National Footprint WELLSTAR, a subsidiary of WELL Health Technologies Corp. (TSX: WELL), has completed the acquisition of two strategic billing and back-office service providers. These acquisitions expand WELL’s national billing platform, which now serves medical professionals across six Canadian provinces. WELL Health continues its “buy-and-build” strategy, acquiring fragmented healthcare IT and billing services to create a unified, tech-enabled provider network. By scaling its billing division, WELL increases its recurring revenue and strengthens its position as the largest owner-operator of outpatient clinics in Canada, providing essential administrative infrastructure to thousands of physicians. (Link)
  9. James River Home Health Acquires Golden Rule Hospice to Expand End-of-Life Care Services James River Home Health and Hospice has completed the acquisition of Golden Rule Hospice. This strategic move expands James River’s service area and strengthens its specialized hospice care offerings. The acquisition is part of James River’s effort to build a comprehensive home-based care network that covers both skilled home health and end-of-life services. As the demand for aging-in-place solutions grows, regional providers like James River are increasingly acquiring boutique hospice agencies to achieve better economies of scale and improve clinical outcomes through standardized care models. (Link)
  10. Loma Linda University Health and Kara Health Form Joint Venture for New Hospice Agency Loma Linda University Health (LLUH) has partnered with Kara Health to launch a joint venture called Loma Linda University Hospice. Kara Health is a tech-enabled home care and hospice provider. This partnership combines LLUH’s clinical excellence with Kara Health’s proprietary technology platform to provide high-quality, data-driven end-of-life care. The joint venture aims to improve patient transitions from the hospital to the home and enhance the palliative care experience through remote monitoring and streamlined communication. This model illustrates the growing trend of health systems partnering with startups to modernize home health. (Link)
  11. Palladium Equity Partners Acquires Majority Stake in DME Express from Waypoint Capital Palladium Equity Partners, LLC has announced its acquisition of a majority interest in DME Express, a leading provider of medical equipment services to the hospice industry. The stake was acquired from Waypoint Capital Partners. DME Express specializes in high-touch delivery and management of durable medical equipment (DME), primarily serving hospice and post-acute care facilities. Palladium’s investment is aimed at accelerating the company’s geographic expansion and enhancing its service capabilities. This transaction underscores the increasing interest from private equity in specialized logistics and equipment providers within the value-based care and end-of-life care sectors. (Link)
  12. SportsMed Physical Therapy Expands to 54 Clinics with New Connecticut Locations SportsMed Physical Therapy, a leading provider of physical therapy, chiropractic, and acupuncture services, has opened two new clinics in Connecticut. These openings bring the company’s total to 54 locations across New Jersey and Connecticut. SportsMed, which has received investment from private equity firms, continues to pursue a rapid “de novo” growth strategy alongside strategic acquisitions. The company focuses on a multidisciplinary approach to musculoskeletal health. This expansion reflects the high investor interest in the physical therapy sector due to its predictable revenue streams and the increasing demand for non-invasive pain management solutions. (Link)
  13. Allina Health to join Sutter Health in $26B proposed transaction in Strategic Realignment Allina Health has released a strategic announcement regarding its long-term operational and investment plan for its Minnesota-based health system. The plan includes a focus on clinical service realignment and infrastructure investment to support high-growth areas like cardiovascular and oncology care. While not a sale of the company, the announcement details strategic capital allocations aimed at improving financial stability and patient access. This news is critical for investors monitoring the financial health of non-profit systems and their shift toward outpatient-focused care models in a challenging economic environment for hospitals. (Link)
  14. Providence Explores Strategic Options Including Sale of Providence Health Plan Providence, one of the largest non-profit health systems in the U.S., has announced it is exploring strategic options for the sale of its Providence Health Plan (PHP) division. PHP is a regional health insurer serving hundreds of thousands of members in Oregon and Washington. This potential divestiture is part of Providence’s effort to shore up its balance sheet and focus resources on its core hospital operations. A sale would likely attract interest from major national insurers or private equity groups seeking a foothold in the Pacific Northwest insurance market. (Link)
  15. Valir Health Expands Senior Care Presence in Oklahoma City Valir Health has announced the acquisition of a prominent senior care facility in Oklahoma City, continuing its expansion in the post-acute care and geriatric services sector. Valir Health provides a range of services including inpatient rehabilitation, hospice care, and billing solutions. This acquisition is part of Valir’s broader strategy to consolidate senior living and rehabilitation services within the Oklahoma region. By integrating this new facility, Valir aims to improve care coordination for the elderly population. The deal reflects a regional trend of mid-sized healthcare companies expanding their physical footprint to meet growing geriatric demand. (Link)

Venture Deals

  1. Unnatural Products Raises $45 Million Series B Led by Nextech Invest and Frazier Life Sciences with participation from Northpond Ventures, Cool Springs Financial, and others to Advance Peptide Therapeutics Unnatural Products (UNP), a biotech firm specializing in macrocyclic peptide therapeutics, has secured $45 million in Series B financing. The round was led by Nextech Invest and Frazier Life Sciences, with participation from Northpond Ventures, Cool Springs Financial, and others. The company uses a platform that combines AI and medicinal chemistry to create “unnatural” macrocycles that can hit difficult-to-target intracellular proteins. The capital will be used to advance its lead oncology programs into the clinic and expand its platform capabilities. This funding highlights continued investor confidence in AI-driven drug discovery platforms targeting previously “undruggable” pathways. (Link)
  2. Conduit Health Raises $17 Million Series A Led by Drive Capital to Expand AI-Powered DME Access Conduit Health has raised $17 million in Series A funding led by Drive Capital. Conduit Health operates an AI-powered platform designed to streamline access to Durable Medical Equipment (DME). The platform connects healthcare providers, payers, and suppliers to automate the ordering and fulfillment process, which is traditionally fragmented and manual. The investment will be used to scale the company’s technology and expand its market presence. This deal underscores the venture capital interest in solving administrative bottlenecks within the home health and medical supply chain using modern software-as-a-service (SaaS) models. (Link)
  3. Verily Secures $300 Million Investment Led by Alphabet (NASDAQ: GOOGL) to Advance Precision Health AI Verily, the life sciences subsidiary of Alphabet (NASDAQ: GOOGL), has secured a $300 million investment to accelerate its precision health AI strategy. This funding round, supported by parent company Alphabet and other institutional investors, will focus on scaling Verily’s data-driven clinical research and care management solutions. The company aims to use the capital to further integrate artificial intelligence into its “Lightship” clinical trial platform and its chronic condition management tools. This massive investment signals Google’s long-term commitment to becoming a dominant player in the convergence of big data, AI, and clinical healthcare. (Link)
  4. Turquoise Health Raises $40 Million Series B Led by Adams Street Partners with participation from Andreessen Horowitz (a16z) and BoxGroup to Power Healthcare Price Transparency Turquoise Health, a healthcare pricing platform, has raised $40 million in Series B funding led by Adams Street Partners, with participation from Andreessen Horowitz (a16z) and BoxGroup. Turquoise Health provides software that enables hospitals and payers to comply with price transparency regulations and manage data-driven contracts. The company intends to use the funds to expand its “ClearContract” platform, which automates the negotiation and management of payer-provider contracts. This investment highlights the growing importance of data transparency tools as healthcare shifts toward value-based care and more complex reimbursement models. (Link)
  5. Condor Software Raises $24 Million Series A Led by Bessemer Venture Partners with participation from Casdin Capital and existing investors for Clinical Trial Finance Management Condor Software has secured $24 million in Series A funding led by Bessemer Venture Partners, with participation from Casdin Capital and existing investors. Condor Software provides a specialized financial management platform for biotech companies to track and manage the complex costs associated with clinical trials. The company aims to replace manual spreadsheets with automated workflows that integrate with clinical and financial data. The new capital will be used to scale its engineering team and accelerate product development, reflecting the niche but high-value demand for fintech solutions tailored specifically to the life sciences industry. (Link)
  6. RAAPID Secures Series A Extension Led by Celesta Capital to Scale Neuro-Symbolic AI for Medical Coding RAAPID has secured a Series A extension funding round led by Celesta Capital to scale its “Neuro-Symbolic” AI-powered medical coding and risk adjustment platform. The company’s technology helps healthcare providers and insurers automate the complex process of clinical documentation and coding, ensuring accurate reimbursement. By combining deep learning with symbolic AI, RAAPID aims to provide higher accuracy and transparency than traditional LLM models. The funding will support geographic expansion and further R&D. This deal illustrates the shift toward specialized, high-accuracy AI tools for administrative healthcare tasks where error margins are critical. (Link)
  7. Health Universe Raises $6 Million Seed Round Led by Eniac Ventures for AI Agents in Medical Workflows Health Universe, a platform for developing and deploying AI “agents” for medical workflows, has raised $6 million in a seed funding round led by Eniac Ventures. The platform allows developers and clinicians to collaborate on AI models that automate specific clinical tasks, such as surgery scheduling or pathology reporting. Health Universe provides the infrastructure for hosting and running these models securely in a compliant environment. This investment highlights the emerging “AI-as-a-Service” model within healthcare, where platforms provide the tools for specialized, agentic AI to be integrated into daily hospital operations. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Mar 16th, 2026

LECO_Weekly-Healthcare-News_3-16-2026Download
  1. Aveanna Healthcare Holdings (NASDAQ: AVAH) to acquire Trivest-backed Family First Homecare, expanding pediatric home care footprint and leveraging cash and credit facilities for accretive growth via its financial sponsors Bain Capital and J.H. Whitney Capital Partners Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH) agreed to acquire Family First Holding, LLC, a multi-state pediatric home care provider backed by growth investor Trivest Partners since 2021, in a strategic platform expansion deal. The transaction, funded through cash on hand and Aveanna’s existing short-term credit facility, is expected to close in Q2 2026 subject to customary conditions, underscoring lender confidence in the issuer’s credit profile. For Trivest, the exit crystallizes value created since its minority investment, while Aveanna investors gain access to 27 locations across seven states and deeper exposure to high-acuity, home-based pediatric care. Management highlights the acquisition as aligned with Aveanna’s strategy to scale specialized care models and deliver enhanced value to payors and stakeholders. (Link)
  2. Veeva Systems (NYSE: VEEV) pays $100 million for AI brand engagement platform Ostro, enhancing life sciences commercial cloud offering Veeva Systems Inc. (NYSE: VEEV) has acquired Ostro, an AI-powered brand engagement platform, for $100 million to strengthen its commercial suite for life sciences clients. The acquisition integrates AI-driven customer engagement and personalization into Veeva’s CRM and marketing stack. Shareholders gain incremental growth opportunities as pharma and biotech customers increase digital and AI spend. The all-cash deal aligns with Veeva’s strategy of adding focused applications that drive higher wallet share and stickiness across large enterprise accounts. (Link)
  3. Medtronic (NYSE: MDT) to acquire neurovascular device company, Scientia Vascular, for $550 million, bolstering high-growth stroke and neuro interventions pipeline.Medtronic plc (NYSE: MDT) has agreed to acquire a neurovascular device company, Scientia Vascular, for approximately $550 million, targeting expansion in stroke and neuro-interventional therapies. The acquisition enhances Medtronic’s innovation pipeline and positions the company to compete more aggressively in high-growth, procedure-driven markets. Equity investors in Medtronic gain exposure to a differentiated product portfolio that can support long-term revenue growth and margin expansion. The transaction will likely be funded through Medtronic’s balance sheet and is consistent with its strategy of bolt-on acquisitions in key therapy areas. (Link)
  4. RadNet (NASDAQ: RDNT) to acquire AI radiology company Gleamer, advancing imaging AI capabilities and strengthening diagnostic services moat. RadNet, Inc. (NASDAQ: RDNT) has agreed to acquire Gleamer, an AI radiology company, to integrate advanced AI tools into its large-scale imaging network. The acquisition is expected to enhance diagnostic accuracy, workflow efficiency, and throughput across RadNet’s centers. Equity investors view the move as strategic positioning in AI-enabled diagnostics, potentially improving margin structure and differentiation against competitors. The deal also gives Gleamer’s technology a scaled deployment channel, increasing data volume and algorithm performance over time. (Link)
  5. MedImpact Holdings acquires MHW Benefit Partners and MSL Captive Solutions to build integrated risk and pharmacy benefits platform for self-funded employers. MedImpact Holdings, Inc., a leading independent health solutions and pharmacy benefit company, acquired MHW Benefit Partners and MSL Captive Solutions to expand its suite of alternative risk-financing offerings for employer clients. The deal broadens MedImpact’s capabilities into captives and stop-loss insurance, enabling small and mid-sized employers to access structures historically used by large self-insured groups. Investors in MedImpact gain exposure to higher-margin, capital-efficient risk-management services that complement the core PBM and clinical programs. The acquisitions are expected to drive cross-sell opportunities across TPAs, transparent networks, drug savings, and member care solutions, deepening client stickiness and recurring revenue. (Link)
  6. Prospect Medical Holdings sells final Crozer hospital for $1 million, marking distressed exit from Pennsylvania market and transfer to local nonprofit sponsor. Prospect Medical Holdings has completed the divestiture of its final Crozer Health hospital for approximately $1 million, effectively exiting its troubled Pennsylvania hospital portfolio. The low valuation underscores ongoing financial distress and operational challenges in safety-net acute care assets, impacting prior private equity investors in the platform. The facility transitions to a local nonprofit sponsor, shifting governance away from financial sponsors toward mission-driven community operators. Lenders and bondholders will monitor post-transaction capital commitments and turnaround plans as the new owner seeks to stabilize operations and address deferred investment needs. (Link)
  7. CSG.BIO partners with and Asian Egg Bank, adding specialized fertility assets backed by Corbel to its global reproductive health platform. CSG.BIO has entered a partnership with Hanabusa IVF and Asian Egg Bank, acquiring a specialized fertility clinic and donor egg bank focused on Asian patients to expand its reproductive health platform. The deal is supported by capital from Corbel, providing growth funding to scale the mini-IVF and donor egg offerings across new markets. Investors in CSG.BIO gain differentiated assets in a high-growth, cash-pay fertility segment with strong patient demand. The transaction reflects continued private equity and sponsor interest in fertility platforms with unique clinical models and demographic specialization. (Link)
  8. BV Investment Partners takes stake in Moxe Health, backing healthcare data exchange platform in value-based care ecosystem. BV Investment Partners has made an investment in Moxe Health, a healthcare data exchange and interoperability platform focused on payor-provider connectivity. The capital infusion will support product development and commercial expansion as value-based care models require richer, real-time data flows. For BV’s limited partners, the deal offers exposure to a high-growth, recurring revenue SaaS model in healthcare IT infrastructure. Moxe plans to leverage the partnership to accelerate integrations with payors and providers, enhancing network effects and stickiness. (Link)
  9. MedCare Express sold to physician group AMKY Health CT, LLC, transitioning a scaled urgent and primary care practice to new clinical owners. MedCare Express, an integrated urgent and primary care center serving over 30,000 active patients in the Greater Hartford area, has been sold to private physician practice group AMKY Health CT, LLC. Founded in 2007, MedCare Express has built a strong community footprint and recurring patient base, making it an attractive cash-flow asset for physician investors. The buyer plans to support growth while preserving quality standards, signaling a long-term, clinical-operator-led strategy rather than a near-term financial engineering approach. Existing stakeholders benefit from continuity of care and potential service expansion under new ownership. (Link)
  10. Baptist Health to acquire South Arkansas Regional Hospital in El Dorado, extending nonprofit system’s regional footprint and strengthening community care. Baptist Health has signed an agreement to acquire South Arkansas Regional Hospital in El Dorado, Arkansas, adding a key community hospital to its regional nonprofit health system. The acquisition brings the hospital under a larger balance sheet, providing access to capital for facility upgrades and service expansion. For bondholders and donors supporting Baptist Health, the transaction represents a strategic bet on stabilizing rural and small-market acute care. Local stakeholders are expected to benefit from integration into Baptist’s broader clinical network and potential economies of scale in operations and procurement. (Link)
  11. HouseWorks acquires A Caring Experience, scaling private-pay home care footprint and consolidating in the New England market via its financial sponsors InTandem Capital Partners and BPEA Private Equity HouseWorks, a home care provider backed by institutional investors, has acquired A Caring Experience to deepen its presence in the New England home care market. The deal adds local scale, enhances caregiver capacity, and broadens referral relationships in a competitive private-pay and Medicaid-waiver environment. Investors in HouseWorks are positioning for demographic tailwinds and further roll-up opportunities in non-medical home care. The combination is expected to generate operating synergies across scheduling, back-office functions, and recruitment, improving margin profile over time. (Link)
  12. Dynamic Access acquires PICC STAT in Minnesota, expanding vascular access services footprint for clinical and financial sponsors via its financial sponsor RiverGlade Capital Dynamic Access has acquired PICC STAT, a Minnesota-based vascular access provider, in a tuck-in acquisition to grow its specialized PICC and vascular access services network. The deal strengthens Dynamic Access’s regional coverage, allowing payors and health systems to rely on a larger contracted network for on-demand vascular access. Financial sponsors backing outsourced clinical service platforms benefit from increased density, which supports higher route efficiency and utilization. The acquisition underscores ongoing consolidation in niche procedural services where scaled operators can secure better payer contracts and operating leverage. (Link)
  13. Residential Home Health and Hospice acquires Covenant, building scale in home health and hospice across regional markets for sponsor-backed platform. Residential Home Health and Hospice has announced the acquisition of Covenant, adding a substantial home health and hospice footprint to its existing platform. The deal expands the provider’s presence across multiple states, increasing patient census and strengthening referral networks. Sponsor investors behind Residential are pursuing a scale and density strategy in post-acute care, where larger platforms can better manage labor, compliance, and payor relationships. The transaction positions the combined organization to capture more value in value-based and episodic payment arrangements. (Link)
  14. Health Recovery Solutions acquires Rimidi, expanding remote care programs and chronic disease management capabilities for digital health investors. Health Recovery Solutions has acquired Rimidi to broaden its remote patient monitoring and chronic disease management solutions. The combined platform will offer providers and payors an integrated suite for virtual care, data analytics, and patient engagement. Investors see the transaction as consolidation in a crowded remote monitoring space, aiming to reach sustainable scale and differentiated outcomes data. The deal positions the company to participate more fully in value-based arrangements tied to chronic condition control. (Link)
  15. Guideway Care acquires Waypoint Healthcare Solutions, expanding patient navigation and care coordination platform for payor and provider sponsors. Guideway Care has acquired Waypoint Healthcare Solutions to enhance its patient navigation and care coordination capabilities. The transaction deepens Guideway’s relationships with payors and providers seeking to reduce avoidable utilization and improve outcomes. Financial sponsors backing navigation and care-management platforms expect enhanced cross-sell and contract win rates from the expanded offering. The combined entity is positioned to integrate analytics, staffing, and workflow tools under a single, scalable model. (Link)
  16. Centerpoint Health Winchester acquires local medical practice, expanding primary care capacity under community health center sponsorship. Centerpoint Health Winchester has announced the acquisition of a local medical practice, adding providers and patient volume to its community health operations. The deal supports Centerpoint’s mission-driven growth strategy, bringing more primary care access under a single organizational umbrella. For grantors and community-focused investors, the transaction aligns with population health and access objectives rather than pure financial returns. The additional capacity may improve economies of scale in administration and payer contracting for the center. (Link)
  17. ECU Health agrees to sell home health and hospice unit to Liberty, pending state review, rebalancing portfolio toward core acute services ECU Health has agreed to sell its home health and hospice operations to Liberty, subject to state regulatory review. The divestiture allows ECU Health to refocus capital and management attention on its core acute care and hospital assets. Liberty, a home health and hospice operator, gains additional scale and access to new markets, enhancing network density for its investors and lenders. The transaction continues a broader trend of health systems exiting ancillary service lines to specialized operators. (Link)
  18. Sonida Senior Living (NYS:SNDA) completes $1.8 billion strategic merger with CNL Healthcare Properties, deepening senior housing scale and institutional investor backing. Sonida Senior Living has closed a strategic merger with non-traded REIT CNL Healthcare Properties Inc., valuing the combined senior housing platform at approximately $1.8 billion and significantly increasing real estate scale for equity holders. The transaction gives Sonida access to a larger portfolio of senior living communities and a broader institutional capital base anchored by CNL’s healthcare-focused investors. The combined platform is positioned to pursue operational efficiencies, refinancings, and future portfolio optimization to enhance returns. Equity stakeholders in both entities gain from diversification across markets and care levels, while debt providers benefit from greater asset backing. (Link)
  19. Biomemory acquires Catalog Technologies, preparing DNA data storage deployment in data centers in H2 2026 for deep-tech backers. DNA data storage startup Biomemory has acquired Catalog Technologies, consolidating IP and capabilities to commercialize DNA-based data storage solutions. The combined company plans data center deployments in the second half of 2026, targeting hyperscale and enterprise customers seeking ultra-dense, long-term storage. Deep-tech and climate-conscious investors see potential in DNA storage’s low energy footprint compared to traditional media. The acquisition accelerates time-to-market and strengthens Biomemory’s competitive position in a nascent but strategically important storage category. (Link)
  20. Aditxt (NAS: ADTX) buys Ignite Proteomics for $36 million in preferred stock and secures $2.88 million note financing, strengthening precision medicine portfolio. Aditxt has acquired Ignite Proteomics in a stock-based transaction valued at $36 million in preferred equity, alongside securing $2.88 million in note financing. The deal brings proteomics capabilities into Aditxt’s precision medicine and immune monitoring portfolio, offering investors upside in biomarker-driven platforms. The structure, heavily equity-based with incremental debt, reflects a capital-efficient approach for a growth-stage company. Noteholders gain exposure to potential value inflection from integration and commercialization of Ignite’s technologies. (Link)

Venture Deals

  1. Amigo AI Secures $11 Million Series A Led by Madrona to Scale Patient-Facing Clinical AI Agents with significant participation from Optum Ventures Amigo AI has successfully raised $11 million in a Series A funding round led by Madrona, with significant participation from Optum Ventures. This capital infusion brings the company’s total funding to $17 million, following a previous seed round supported by General Catalyst and GSV Ventures. The investment is earmarked for the expansion of Amigo’s “digital residency” platform, which trains AI agents in simulated clinical environments to ensure a 100% safety pass rate before patient interaction. For venture investors, Amigo represents a high-growth opportunity to address the global healthcare workforce shortage by automating complex clinical workflows like triage and care navigation across 100+ languages. (Link)
  2. Arya Secures $21 Million Series A to Scale Relationship OS Platform for Modern Couples Arya has successfully raised $21 million in a Series A funding round led by Canvas Ventures, with participation from existing investors including General Catalyst and SV Angel. This capital injection is aimed at accelerating the development of its “Relationship OS,” a technology platform designed to help couples navigate emotional, financial, and logistical complexities through data-driven insights. For venture investors, the deal represents a strategic entry into the rapidly growing “Family Tech” and wellness space, leveraging AI to provide personalized coaching and conflict-resolution tools. The funding will support product engineering and the expansion of Arya’s user base as it seeks to define a new category of proactive mental health and relationship maintenance. (Link)
  3. Carefam Raises $10.5 Million to Scale AI-Driven Healthcare Recruitment Platform led by Pitango Venture Capital Carefam has successfully raised $10.5 million in a new funding round, bringing its total capital raised to $14 million. The investment is aimed at expanding its specialized conversational AI platform, which automates the end-to-end hiring process for hospitals, long-term care facilities, and home care providers. For venture investors, Carefam addresses the critical global healthcare labor shortage by streamlining credential screening, interview scheduling, and onboarding through vertically integrated AI agents. The funding will allow the company to enhance its technology and scale its operations to help healthcare HR departments reduce administrative friction and accelerate the placement of essential clinical staff. (Link)
  4. Qualified Health Eyes Series A Funding Following $30 Million Seed Round Led by SignalFire, Healthier Capital, and Town Hall Ventures Qualified Health, a pioneer in healthcare orchestration, is reportedly preparing for a Series A funding round to scale its AI-driven platform that streamlines clinical and administrative workflows. This follows a substantial $30 million seed investment led by SignalFire, Healthier Capital, and Town Hall Ventures, which allowed the company to deploy its “operating layer” across major systems like University of Texas and Jefferson Health. For venture investors, the startup represents a high-potential infrastructure play that integrates with EHRs to automate summarization and prior authorization. Potential new investors such as NEA and General Catalyst are being watched as the company targets a nine-figure valuation while navigating rigorous generative-AI safety and regulatory hurdles. (Link)
  5. Translucent Secures $27 Million Series A Led by GV (Google Ventures) to Revolutionize Healthcare Financial Operations Translucent has closed a $27 million Series A funding round led by GV, with participation from existing investors including Benchmark and Unusual Ventures. This capital injection is dedicated to scaling the company’s AI-driven financial orchestration platform, which targets the “existential financial crisis” facing hospitals by automating complex revenue cycle and accounts payable workflows. For venture investors, Translucent represents a critical infrastructure play that addresses thin hospital margins through autonomous financial intelligence. The funding will be used to accelerate product development and expand the company’s footprint across health systems seeking to replace manual, error-prone administrative tasks with real-time, transparent financial data management. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Mar 9th, 2026

LECO_Weekly-Healthcare-News_3.9.2026Download
  1. Race to Contain Iran War Oil Shock as Crude Surges Past 100 Dollars, Markets Slide and Fears Grow Over Prolonged Energy Disruption and Global Inflation Spike G7 finance ministers are preparing an emergency meeting to discuss a possible coordinated release of strategic oil reserves after the Iran war pushed crude above 100 dollars a barrel for the first time since 2022, with Brent briefly nearing 120 dollars. The US‑Israel conflict with Iran has severely disrupted shipments through the Strait of Hormuz, a route that normally carries about a fifth of global oil, driving a sharp spike in crude and gas prices and triggering stock‑market falls. G7 officials fear prolonged fighting could keep energy flows constrained, entrench higher inflation and slow global growth. (Link)
  2. Universal Health Services (NYSE: UHS) to Acquire Talkspace (NASD: TALK) for $5.25/Share in $835 Million All‑Cash Deal to Build National Virtual Behavioral Health Platform Universal Health Services (UHS) has signed a definitive agreement to acquire virtual behavioral health provider Talkspace for $5.25 per share, implying an enterprise value of about $835 million, funded via UHS’s existing revolving credit facility. Talkspace, which generated roughly $229 million in 2025 revenue and delivered more than 1.6 million therapy and psychiatry sessions, brings a network of about 6,000 licensed professionals across all U.S. states, D.C. and Puerto Rico. UHS expects the deal, unanimously approved by both boards and targeted to close in Q3 2026 pending shareholder and regulatory approvals, to be slightly accretive to adjusted EPS in the first year and to accelerate its outpatient and telehealth behavioral health strategy. (Link)
  3. Agilent Technologies (NYSE: A) to Acquire Biocare Medical for $950 Million Cash, Expanding High-Growth Pathology Antibody Platform and Targeting EPS Accretion Within 12 Months Agilent Technologies (NYSE: A) has signed a definitive agreement to acquire Biocare Medical, a high-growth clinical pathology specialist, in an all-cash deal valued at $950 million. Biocare, a leader in IHC, ISH and FISH solutions with more than 300 antibodies and over $90 million of 2025 revenue, has delivered double-digit revenue and profit growth since 2021. The transaction will expand Agilent’s pathology portfolio, strengthen its U.S. footprint and accelerate antibody menu development. Management expects the deal to be accretive to growth, margins and non-instrument mix in year one and to EPS about 12 months post-close. (Link)
  4. Saisystems Health and Serent Capital Partner to Scale AI-Enabled RCM and EHR Solutions Saisystems Health, a provider of technology-enabled revenue cycle management (RCM) and electronic health records (EHR) for post-acute care, has announced a strategic partnership with private equity firm Serent Capital. While the specific financial terms were not disclosed, the investment is aimed at accelerating Saisystems’ product innovation, specifically enhancing its AI capabilities to streamline clinical workflows and financial performance for skilled nursing facilities and physician groups. The partnership leverages Serent’s expertise in scaling healthcare technology companies to expand Saisystems’ market footprint. (Link)
  5. Integration Health Expands Portfolio with Acquisition of Perfusion Life via its financial sponsor 1315 Capital Integration Health has successfully completed the acquisition of Perfusion Life, a leading provider of perfusion staffing and management services. This strategic move is designed to bolster Integration Health’s clinical service offerings across hospitals and surgical centers. By integrating Perfusion Life’s specialized expertise, Integration Health aims to optimize cardiovascular surgical support and staffing efficiency. The acquisition reflects a broader strategy of consolidating niche clinical services to provide a more comprehensive, integrated care delivery model for healthcare systems nationwide. (Link)
  6. Surgery Partners Acquires Preferred Vascular Group to Expand Multispecialty Surgical Platform  its financial sponsor Bain Capital Surgery Partners, Inc. has acquired Preferred Vascular Group (PVG), a provider of vascular care services. This acquisition integrates PVG’s high-quality vascular access centers into Surgery Partners’ extensive national network of ambulatory surgical centers. The deal is intended to enhance Surgery Partners’ specialty care capabilities, particularly in the outpatient vascular space, providing patients with more accessible and cost-effective treatment options. This move follows trends of shifting high-acuity procedures to lower cost, outpatient environments. (Link)
  7. Gedeon Richter Expands Women’s Health Portfolio through Acquisition of Celmatix’s Drug Discovery Assets Global pharmaceutical company Gedeon Richter has acquired the women’s health drug discovery portfolio from Celmatix Inc. The deal includes several preclinical programs focused on first-in-class treatments for conditions such as PCOS and endometriosis. This acquisition strengthens Gedeon Richter’s position as a leader in women’s healthcare by integrating Celmatix’s AI-driven “Transcriptomic Cohort” data to identify novel therapeutic targets. The partnership emphasizes a shared commitment to addressing underserved medical needs in reproductive health through cutting-edge genomic research and clinical development. (Link)
  8. Quantum Health Bolsters Virtual Care Strategy with Acquisition of CirrusMD via its financial sponsors Great Hill Partners and Warburg Pincus. Quantum Health, a leading consumer healthcare navigation company, has acquired CirrusMD, a provider of physician-led integrated virtual care. This acquisition enables Quantum Health to integrate CirrusMD’s “text-first” virtual care platform into its navigation services, offering members immediate access to physicians. The synergy aims to reduce healthcare costs and improve outcomes by closing gaps in care through early intervention. The deal reflects Quantum Health’s strategy to provide a seamless, end-to-end healthcare experience that combines human navigation with advanced digital health tools. (Link)
  9. TPG Capital Partners with Findhelp to Enhance Social Care Access for Underserved Populations Global alternative asset firm TPG, through its Rise Fund, has partnered with Findhelp, the leading social care network in the United States. The investment is geared toward scaling Findhelp’s platform, which connects individuals in need with local social service organizations. TPG’s involvement will support Findhelp in expanding its reach among healthcare providers, insurers, and government agencies. By addressing social determinants of health (SDOH), the partnership aims to improve health outcomes and equity for millions of Americans by streamlining the referral process for food, housing, and financial assistance. (Link)
  10. American Reproductive Centers Acquires Mississippi Fertility Institute for $4.25 Million Alabama-based American Reproductive Centers (ARC) has expanded its regional presence by acquiring the Mississippi Fertility Institute in a deal valued at $4.25 million. This acquisition is part of ARC’s strategic effort to increase access to advanced reproductive technologies and fertility treatments across the Southeast. By integrating the Jackson-based clinic into its network, ARC plans to upgrade facilities and introduce new clinical protocols to improve patient success rates. The deal underscores a growing trend of regional consolidation within the highly specialized fertility and IVF market. (Link)
  11. DoseSpot and Arrive Health Merge to Improve Prescription Access and Price Transparency via its financial sponsors Bain Capital Tech Opportunities, PSG and UPMC Enterprises DoseSpot, a leading e-prescribing platform, and Arrive Health, a provider of real-time prescription benefit tools, have announced a merger. This combination aims to create a unified platform that integrates clinical workflows with financial transparency, allowing clinicians to see accurate drug pricing at the point of care. The merger is designed to improve medication adherence and reduce administrative burdens for providers. By joining forces, the entities seek to solve the critical challenge of drug affordability, ensuring patients can access the most cost-effective medications prescribed by their doctors. (Link)
  12. Adobe Population Health Acquires Eventa LLC to Integrate Respiratory Care Solutions Adobe Population Health has expanded its clinical service suite through the acquisition of Eventa LLC, a specialist in respiratory care management. This acquisition allows Adobe to offer specialized services for patients with chronic respiratory conditions, such as COPD and asthma, within its population health management framework. By incorporating Eventa’s expertise, Adobe aims to reduce hospital readmissions and improve the quality of life for high-risk patient populations. The move highlights Adobe’s commitment to building a comprehensive, multi-disciplinary approach to managing complex chronic diseases. (Link)
  13. Freeman Health System to Acquire Four Arkansas Hospitals from Community Health Systems (CHS) Community Health Systems (CHS) has signed a definitive agreement to sell four of its Arkansas-based hospitals to Freeman Health System. The transaction includes facilities in El Dorado, Springdale, and Bentonville. This divestiture is part of CHS’s ongoing portfolio optimization strategy to focus on core markets. For Freeman Health System, the acquisition represents a significant geographic expansion, allowing the non-profit system to provide a broader continuum of care to residents in the Arkansas region while investing in facility upgrades and clinical services. (Link)
  14. MUSC Health Expands Statewide with $111 Million Acquisition of Palmetto Primary Care MUSC Health has announced a $111 million deal to acquire Palmetto Primary Care Physicians, one of the largest independent multi-specialty groups in South Carolina. This strategic acquisition significantly broadens MUSC’s primary care footprint, adding over 100 providers across 30 locations. The investment is focused on creating a more seamless “hub-and-spoke” model of care, ensuring patients have easier access to MUSC’s specialized academic medical services through their local primary care offices. The deal reflects MUSC’s mission to provide comprehensive, integrated healthcare coverage throughout the state. (Link)
  15. Seal Shield Acquires Vioguard to Expand UV-C Sanitization Solutions in Healthcare Seal Shield, a leader in medical-grade infection control hardware, has acquired Vioguard, a pioneer in UV-C LED disinfection technology. This acquisition enhances Seal Shield’s portfolio of sanitization solutions designed to eliminate pathogens on high-touch surfaces in clinical environments. By integrating Vioguard’s patented UV-C technology, Seal Shield aims to offer more robust, automated disinfection tools to hospitals and clinics, helping to reduce healthcare-associated infections (HAIs). The deal positions Seal Shield as a comprehensive provider of both antimicrobial hardware and advanced disinfection systems. (Link)
  16. National Healthcare Properties and Discovery Senior Living Complete $64 Million Acquisition National Healthcare Properties, in partnership with Discovery Senior Living, has closed a $64 million acquisition of a senior housing portfolio. This investment is part of a broader strategy to modernize and expand senior living communities to meet the rising demand for high-quality assisted living and memory care services. Discovery Senior Living will manage the properties, implementing its “experiential” living model. The deal highlights the continued interest of institutional real estate investors in the senior housing sector, driven by favorable demographic trends and the need for specialized care facilities. (Link)
  17. Patient Advocate Foundation and PAN Foundation Announce Landmark MergerThe Patient Advocate Foundation (PAF) and the Patient Access Network (PAN) Foundation have announced their intention to merge, creating a powerhouse in the patient assistance sector. This merger will combine PAF’s case management and navigation services with PAN’s financial assistance programs for underinsured patients. By joining forces, the organizations aim to provide a more holistic support system for individuals facing life-threatening and chronic illnesses. The unified entity will focus on reducing financial barriers to care and improving health equity through expanded advocacy and direct patient support services. (Link)

Venture and Other News:

  1. Minnesota Medical Technologies Secures $20 Million Series A Led by Versant Ventures Minnesota Medical Technologies (MMT) has closed a $20 million Series A funding round led by Versant Ventures, with participation from existing investors. MMT is a medical device firm focused on developing innovative solutions for urological and GI health. The capital will be used to accelerate the development and clinical validation of its flagship fecal incontinence treatment device. MMT aims to address a significant unmet need in the market with its minimally invasive technology, and the new funding will support toward FDA clearance and commercial launch in the U.S. market. (Link)
  2. llumia Ventures Leads $20.5M Series B in Greater Good Health; DaVita Venture Group and Blue Cross of Idaho’s Granite Financial Join, with $12.5M Debt Facility from HSBC Innovation Banking Greater Good Health, a value-based primary care provider centered on nurse practitioners, raised $20.5 million in Series B funding led by Allumia Ventures, with participation from DaVita Venture Group, Granite Financial Holdings (Blue Cross of Idaho’s investment arm), and existing investors including Optum Ventures and Flare Capital Partners. The company also secured up to $12.5 million in venture debt from HSBC Innovation Banking. Serving over 200,000 patients, Greater Good Health will use the funds to expand its value-based care model, deepen payer partnerships, and extend its geographic footprint, addressing primary care shortages and rising healthcare costs. (Link)
  3. NexCure Raises $19 Million Series A to Advance Immuno-Oncology Pipeline NexCure, a clinical-stage biopharmaceutical company, has successfully raised $19 million in a Series A funding round. While specific lead investors were not named in initial reports, the round included participation from several prominent life science venture firms. The funding will be directed toward advancing NexCure’s lead candidate through Phase 1 clinical trials and supporting the discovery of new drug targets for cancer immunotherapy. NexCure utilizes a proprietary functional screening platform to identify novel proteins that modulate the immune system, aiming to develop therapies for patients who do not respond to existing treatments. (Link)
  4. Sage Secures $65 Million Series C Led by Goldman Sachs including ANEW Capital and Maveron to Scale AI Senior Care Platform Sage, a technology platform designed to modernize eldercare, has raised $65 million in a Series C funding round led by Goldman Sachs Asset Management. The round also saw participation from ANEW Capital and Maveron. Sage’s platform uses AI to help senior living staff monitor residents more effectively, prioritizing care based on real-time data to prevent emergencies. This new capital will be used to scale Sage’s operations, enhance its AI algorithms, and expand its reach into more senior living communities across the United States, addressing the critical staffing shortages in the industry. (Link)
  5. Science Corporation Closes $230 Million Series C to Commercialize BCI Retinal Implant backed by Founders Fund, Lux Capital, and Paradigm Science Corporation, a leader in brain-computer interface (BCI) technology, has raised $230 million in a Series C round. The funding was backed by a diverse group of investors, including Founders Fund, Lux Capital, and Paradigm. The capital is earmarked for the commercialization of its PRIMA retinal implant, a sub-retinal device designed to restore vision in patients with geographic atrophy due to age-related macular degeneration. Following successful clinical results, Science Corp aims to use this massive infusion of capital to build out its manufacturing capabilities and prepare for a global product launch. (Link)
  6. UnityAI Raises $8.5 Million Seed Round to Deploy AI Agents for Healthcare Workforce led by Max Ventures and General Catalyst UnityAI has secured $8.5 million in seed funding led by Max Ventures and General Catalyst. The startup is developing AI-driven “agents” designed to automate administrative tasks and optimize patient flow within hospital settings. The goal of the technology is to alleviate the burnout experienced by healthcare workers by handling scheduling, bed management, and documentation. This initial capital will allow UnityAI to expand its engineering team and launch pilot programs with several large health systems, proving the efficacy of AI in managing complex hospital operations and improving staff retention. (Link)
  7. Grow Therapy Hits $3 Billion Valuation Following New Funding Round Led by TCV with participation from Transformation Capital and SignalFire Mental health platform Grow Therapy has reached a “unicorn” valuation of $3 billion after a new funding round led by TCV, with participation from Transformation Capital and SignalFire. Grow Therapy provides an integrated platform that helps independent therapists manage their practices while connecting patients with affordable, insurance-covered mental health care. The fresh capital will be used to further develop its AI-driven matching tools and expand its network of providers. The high valuation underscores the surging investor interest in mental health startups that solve the accessibility and affordability crisis. (Link)
  8. KeyCare Raises $27.4 Million to Scale AI-Powered Epic-Based Virtual Care featuring 8VC, LRVHealth, and Health Catalyst Capital KeyCare, the nation’s first Epic-based virtual care company, has raised $27.4 million in a funding round featuring 8VC, LRVHealth, and Health Catalyst Capital. KeyCare allows health systems to expand their virtual care capacity by providing access to a network of independent “virtualist” providers who share the same EHR platform. This funding will support the expansion of KeyCare’s AI capabilities, which help triaging patients and streamlining the virtual visit process. By staying within the Epic ecosystem, KeyCare ensures seamless data sharing and continuity of care between virtual visits and in-person health system services. (Link)
  9. Polares Medical Raises $50 Million Series C for U.S. Expansion of Mitral Valve Technology led by Decheng Capital and Endeavour Vision Polares Medical, a clinical-stage medical device company, has closed a $50 million Series C round led by Decheng Capital and Endeavour Vision. The company is developing the MRace Mitral Reshaping System, a hemi-replacement technology for treating mitral regurgitation. The funding will support the company’s expansion of clinical trials in the United States and the pursuit of regulatory approvals. Polares aims to provide a more physiological solution for heart valve repair, and this investment signifies strong investor confidence in the company’s unique approach to structural heart disease. (Link)
  10. Teen-Built AI Calorie App “Cal AI” Generates $40 Million and Gains Interest from MyFitnessPal Cal AI, an AI-powered calorie-tracking app built by a 19-year-old entrepreneur during high school, has reportedly generated $40 million in revenue and attracted significant investment interest, including talks with MyFitnessPal and various Silicon Valley VCs. The app uses advanced computer vision to estimate caloric intake from photos of food with high accuracy. The success of the app highlights the power of “solopreneur” developers in the AI space. While a formal venture round hasn’t been closed, the founder is currently evaluating offers to scale into a broader metabolic health platform. (Link)
  11. Ease Health Emerges from Stealth with $41 Million Led by Andreessen Horowitz (a16z) with support from Benchmark and F-Prime Capital. Ease Health has launched with $41 million in funding led by Andreessen Horowitz (a16z), with support from Benchmark and F-Prime Capital. The company is building what it describes as the “operating system for behavioral health,” a comprehensive software suite that integrates clinical notes, billing, and patient engagement for mental health clinics. By automating the “back-office” burden, Ease Health aims to allow therapists to focus more on patient care. The investment will be used to scale the platform nationally and integrate AI tools that help clinicians track patient progress over time. (Link)
  12. Procode AI Raises $4 Million in Seed Funding to Automate Medical Coding round led by Eniac Ventures and Afore Capital Procode AI, a startup utilizing generative AI to automate medical coding and billing, has raised $4 million in a seed round led by Eniac Ventures and Afore Capital. The company’s platform analyzes clinical documentation in real-time to assign accurate medical codes, reducing errors and speeding up the reimbursement process for providers. This funding will be used to enhance the platform’s accuracy across different medical specialties and to expand the sales team. Procode AI enters a competitive market but aims to differentiate itself through its deep integration with existing EHR systems. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Feb 23rd, 2026

LECO_Weekly-Healthcare-News_2.23.2026Download
  1. Trump’s Section 122 Tariffs Hit UK, EU Hardest as Supreme Court Strikes Down IEEPA Levies, Benefiting Brazil, China, India The U.S. Supreme Court ruled 6-3 that President Trump wrongly used IEEPA for tariffs, prompting a shift to 15% global duties under Section 122 of the 1974 Trade Act. Trade-weighted averages rise for UK (+2.1 points), EU (+0.8), Japan (+0.4), South Korea (+0.6), while plunging for Brazil (-13.6), China (-7.1), and India. Experts note heaviest IEEPA-hit nations gain most relief; early deal-makers suffer hikes. EU seeks clarity on prior 15% cap deal. China assesses; India delays trade talks. (Link)
  2. Blue Owl Capital Shares Slide Again as Debt Fund Liquidity Changes and $1.4B Asset Sale Heighten Private Credit Concerns Blue Owl Capital’s stock extended its recent selloff as investors reacted to the firm’s strategy to return capital from one of its private debt funds following a $1.4 billion loan portfolio sale. The alternative asset manager adjusted redemption mechanics for Blue Owl Capital Corp II, opting to return capital through asset sales rather than traditional quarterly liquidity windows. The developments have fueled broader concerns around liquidity, valuation transparency, and structural risks within retail-oriented private credit vehicles. The market reaction underscores growing scrutiny of private credit managers as fundraising slows and pressures rise. (Link)
  3. Cristiano Ronaldo Invests $7.5 Million in Herbalife’s (NYSE: HLF) Pro2col AI Wellness Tech, Secures 10% Stake in Key Subsidiary Herbalife Ltd. (NYSE: HLF) announced soccer superstar Cristiano Ronaldo’s $7.5 million investment in HBL Pro2col Software, LLC, gaining a 10% equity stake. The deal includes service and sponsorship commitments, highlighting Ronaldo’s faith in Pro2col’s AI-driven, personalized wellness platform. Since partnering with Herbalife in 2013, Ronaldo endorsed products like Herbalife24 CR7 Drive. Pro2col uses data for custom plans, tracks habits via Pro2Score, and aids distributors. Now in U.S., Canada, and Puerto Rico beta and expanding to EMEA, boosting their data-centric strategy. (Link)
  4. True North PE Injects INR 150Cr ($16.5M) into High-Growth ACN Healthcare RCM; $20M More Eyed as India’s Outsourcing Boom Accelerates True North Private Equity’s Credit Opportunities Fund I invests Rs 150 crore in ACN Healthcare RCM, a top Revenue Cycle Management provider with India operations and US clients. ACN boasts 68% CAGR growth over three years, employing 3,000+ professionals across four centers. Funds will fuel service expansion, strategic moves, and new facilities. More PE funds eye up to $20M in the round. India’s RCM market surges at 15-17% CAGR, driven by outsourcing, AI, and global demand, with India holding 50% of worldwide talent amid healthcare complexities. (Link)
  5. Danaher (NYSE: DHR) to Acquire Masimo (NASDAQ: MASI) in $9.9 Billion Cash Deal at $180/Share, Boosting Diagnostics with Pulse Oximetry Leader Amid Expected Synergies Danaher Corporation (NYSE: DHR) has agreed to acquire Masimo Corporation (NASDAQ: MASI) for $180 per share in cash, valuing the deal at $9.9 billion enterprise value. The acquisition bolsters DHR’s Diagnostics segment with MASI’s pulse oximetry and patient monitoring tech, expecting high-single-digit revenue growth, $530M+ 2027 EBITDA, $125M cost synergies, and $50M revenue synergies by year five. Deal closes H2 2026 pending approvals; accretive to EPS by $0.15-$0.20 year one, $0.70 by year five. (Link)
  6. Johnson & Johnson (NYSE:JNJ) Explores $20 Billion Sale of DePuy Synthes Orthopedics Unit Amid Spinoff Plans Johnson & Johnson (JNJ.N) is preparing to sell its orthopedics unit, DePuy Synthes, in a deal potentially exceeding $20 billion, targeting private equity firms as top buyers, Reuters reports. The unit, which generated $9.3 billion in 2025 sales from hip, knee, and shoulder implants, was slated for a standalone spinoff within 18-24 months to focus on high-growth segments. J&J is assembling financials for upcoming buyer meetings; large PE firms may team up, with interest from medical device rivals possible. This follows resolutions of most ASR hip lawsuits. CFO eyes tax-free spinoff but open to sales. (Link)
  7. PE-backed Elevate Patient Financial Solutions acquires Centauri Health Solutions’ health systems services unit, expanding Medicaid eligibility, enrolment and complex revenue cycle capabilities across U.S. hospital clients Private equity–backed Elevate Patient Financial Solutions has agreed to acquire Centauri Health Solutions’ Health Systems Services (HSS) unit, a Phoenix-based provider of specialized eligibility and enrollment services for Medicaid and disability programs, out-of-state Medicaid billing, and complex revenue cycle solutions for hospitals and health systems. The deal strengthens Elevate PFS’s position in patient financial engagement and government program eligibility, broadens its national footprint, and is expected to drive cross-selling opportunities across existing provider relationships while supporting uncompensated-care and Medicaid-reliant populations. (Link)
  8. TriSalus Life Sciences (Nasdaq: TLSI) Prices $40M Common Stock Offering at $4.10/Share with 15% Over-Allotment Option, Closing February 23, 2026 TriSalus Life Sciences, Inc. (Nasdaq: TLSI) priced its underwritten public offering of 9,756,100 common shares at $4.10 each, expecting $40 million in gross proceeds before expenses. The oncology-focused medtech firm granted underwriter Lake Street Capital Markets a 30-day option for 1,463,415 additional shares (15% of the offering). Closing is set for February 23, 2026, subject to conditions, via an effective S-3 shelf registration. Funds will support general corporate purposes, amid devices like TriNav for tumor drug delivery and nelitolimod immunotherapy research. (Link)
  9. CenterWell, the healthcare services division of Humana Inc. (NYS: HUM) Expands Florida Footprint with Acquisition of MaxHealth from Arsenal Capital Partners CenterWell, the healthcare services division of Humana Inc., has completed its acquisition of MaxHealth from private equity firm Arsenal Capital Partners and the company’s founder-shareholders. The deal strengthens CenterWell’s presence in Florida, adding a network of 54 owned primary care clinics, four specialty centers, and 24 affiliate clinics across West and South Florida. MaxHealth serves over 120,000 patients, including more than 80,000 in value-based care programs. The acquisition aligns with CenterWell’s strategy to expand its integrated, patient-centered care delivery network and enhance access to high-quality, coordinated healthcare services for seniors and other patients across the region. (Link)
  10. CSD Acquires New Mexico’s Leading Autism Provider BCI in Strategic Merger to Boost Southwest Access, Innovation, and Evidence-Based Behavioral Care Nationwide via its financial sponsors NMS Capital, CD Private Equity, and Goldman Sachs Asset Management Center for Social Dynamics (CSD), a top national autism therapy provider, has acquired Behavior Change Institute (BCI), New Mexico’s premier autism care organization known for clinical expertise and equitable access. Announced February 19, 2026, the deal unites research-driven models, shortening wait times and blending in-person, virtual, and tech-enhanced therapies. CSD CEO Kelly Bozarth hailed it as a “values-driven union” for faster breakthrough care. BCI leaders emphasized scaling their mission nationally while preserving clinical culture. Families retain teams with added CSD tools; the merger advances research, clinician training, and outcomes in underserved areas. (Link)
  11. VB Spine LLC Acquires Exclusive Rights to Augmedics’ FDA-Cleared xvision Spine System®, Bolstering AR Navigation Leadership in Spine Surgery with Nearly 13,000 Cases of Proven Use VB Spine LLC, the largest privately held spine company, announced a definitive agreement to acquire exclusive rights to Augmedics’ groundbreaking xvision Spine System®, the first FDA-cleared AR navigation platform for spine surgery. This move enhances VB Spine’s visualization portfolio, following its recent SpineHawk™ acquisition, and positions it as a global leader in AR-enabled solutions. xvision offers direct-patient visualization, precision, workflow efficiency, and radiation reduction, with nearly 13,000 procedures completed. The deal, expected to close soon pending approvals, supports VB Spine’s strategy to redefine spine care. (Link)
  12. St. David’s HealthCare Acquires Cardiothoracic and Vascular Surgeons, Strengthening Central Texas Cardiovascular Expertise in Strategic Integration Austin-based St. David’s HealthCare, part of HCA Healthcare and local nonprofits, has acquired Cardiothoracic and Vascular Surgeons (CTVS) on Feb. 15. The system, with nine hospitals, 190 care sites, and over 12,600 employees, will keep CTVS’s name, operations, physicians, providers, and 45 staff intact while aligning them under St. David’s. “This integration builds on decades of collaboration to elevate care and innovation,” said CEO David Huffstutler. The move advances cardiovascular standards in Central Texas. (Link)
  13. Epiphany Dermatology Expands Missouri Footprint with Strategic Partnership Joining Regional Dermatology’s St. Louis Clinics in Chesterfield and Festus Epiphany Dermatology has partnered with Regional Dermatology, LLC, founded in 2010 by board-certified dermatologist Sarah Jensen, M.D., to boost its presence in Missouri’s St. Louis market. The deal integrates Jensen’s team—including two advanced practice providers—at two locations: Chesterfield (West) and Festus. This enhances access to high-quality dermatology services like general care, skin cancer treatment, and Mohs surgery. Jensen praised Epiphany’s patient-focused values, while CEO Gheorghe Pusta highlighted the cultural fit and shared expertise. Epiphany now supports operations, marketing, and recruiting, operating 121 locations across 18 states from Austin, Texas. (Link)
  14. Gilead to Acquire Arcellx for Up to $7.8 Billion, Expanding Oncology and Cell Therapy Pipeline Gilead Sciences has agreed to acquire Arcellx in a transaction valued at up to $7.8 billion, strengthening its position in next-generation cell therapies for cancer. Arcellx’s lead programs focus on innovative immunotherapy approaches designed to improve durability and safety in hematologic malignancies. The acquisition builds on Gilead’s broader oncology strategy and deepens its commitment to high-growth, high-innovation therapeutic areas. The deal underscores continued large-cap biopharma appetite for differentiated oncology assets amid competitive cell therapy development. (Link)
  15. Viventium Acquires Apploi to Launch Unified HCM Platform Revolutionizing Post-Acute Care Workforce Management Amid Labor Crisis via its financial sponsor LLR Partners Viventium has acquired Apploi, creating a category-leading human capital management (HCM) platform tailored for post-acute and long-term care providers. The unified system integrates recruiting, credentialing, onboarding, payroll, scheduling, and compliance across all 50 states, addressing labor shortages and fragmented software silos. Viventium CEO Navin Gupta highlighted ending “fractured systems,” while Apploi CEO Adam Lewis emphasized full employee lifecycle support. Serving thousands of providers and hundreds of thousands of employees, the deal closed January 30, 2026. Financial terms undisclosed. (Link)
  16. Invo Fertility (Nasdaq: IVF), Acquires Indianapolis’ Family Beginnings for $760K, Bolstering Midwest Presence and Projecting $9M Clinic Revenue in 2025 Amid Growth Pivot Invo Fertility Inc. (Nasdaq: IVF), based in Sarasota, has acquired the nonclinical assets of Midwest fertility clinic Family Beginnings in Indianapolis for $760,000 in cash and preferred stock. The deal preserves Dr. James Donahue’s leadership and the existing team, with Invo providing operational support and tech investments. Family Beginnings reported $1M revenue and $200K net income for the nine months ended Sept. 30, 2025—18% of Invo’s clinic revenue. Now with four clinics, Invo eyes $9M combined 2025 revenue, up from 2024’s $6.5M total (with $9.1M net loss). CEO Steve Shum calls it an “inflection point,” targeting acquisitions, organic growth, and 2026 expansion via marketing and tech. (Link)
  17. Northwell Health Bolsters South Shore Presence with $9.5M Off-Market Acquisition of Merrick Orthopedic Office Building from Berkeley Capital Northwell Health has expanded its real estate holdings by acquiring a 17,714-square-foot medical office building at 1728-1732 Sunrise Highway in Merrick for $9.5 million in an off-market deal. The property, on 0.46 acres, houses Northwell affiliate Orlin & Cohen Orthopedic Group, with about three years remaining on its lease. Northwell, self-represented, bought from Berkeley Capital LLC, represented by North Village Realty’s Tom Bigansky. The move secures long-term healthcare delivery in South Shore communities, reflecting generational planning and market confidence, Bigansky noted. (Link)
  18. Sensei Biotherapeutics (Nasdaq: SNSE) Acquires Faeth Therapeutics in $200M-Backed Deal to Advance PIKTOR Cancer Therapy Sensei Biotherapeutics (Nasdaq: SNSE) has acquired Faeth Therapeutics, gaining its lead asset PIKTOR—an investigational all-oral combo of serabelisib and sapanisertib targeting the PI3K/AKT/mTOR pathway for endometrial and breast cancers. Concurrently, Sensei secured $200 million in Series B preferred stock financing from top investors like RA Capital, Vivo Capital, and Cormorant. Proceeds will fund Phase 2 topline data in endometrial cancer and a Phase 1b breast cancer trial by end-2026, plus ongoing solnerstotug studies. Post-deal, Faeth holders own 40.8%, investors 54.3%, and prior Sensei shareholders 4.9% on a fully diluted basis. (Link)
  19. Kinderhook Industries to Take Home Health and Hospice Provider Enhabit (NYSE: EHAB) Private in $1.1B Deal Private equity firm Kinderhook Industries has agreed to acquire Enhabit Inc., a Dallas-based home health and hospice services provider, in a transaction valued at approximately $1.1 billion. Under the terms of the deal, Enhabit shareholders will receive $13.80 per share in cash, representing a premium to the company’s recent trading levels. The transaction is expected to close in Q2 2026, at which point Enhabit’s shares will be delisted from the NYSE. The acquisition reflects continued PE interest in the home health and hospice sector amid demographic tailwinds and demand for at-home care services. (Link)

Venture and Other News:

  1. Rainfall Health Secures $15M Series A to Supercharge AI Compliance Platform Amid CMS’s TEAM Mandate Launch, Unlocking $100M+ Revenue for Hospitals Rainfall Health, an AI-driven compliance platform for hospitals, closed a $15 million Series A round led by Two Bear Capital. The funding will expand AI and customer support teams to aid providers under CMS’s new Transforming Episode Accountability Model (TEAM), launched January 1, 2026. TEAM targets high-cost surgeries like joint replacements and spinal fusions, offering 20% revenue boosts—over $100 million per health system—for meeting quality metrics. CEO Eddie Qureshi emphasized high-quality post-acute care. Backed by experts like former VA Secretary David Shulkin, Rainfall sets a national standard for value-based reimbursement and patient outcomes. (Link)
  2. ProSomnus Secures $38 Million Strategic Investment from Catalio Capital to Advance Next‑Generation Smart Sleep Medicine Platform ProSomnus Sleep Technologies, a leader in non‑CPAP Obstructive Sleep Apnea (OSA) therapy, announced a $38 million strategic investment from healthcare investor Catalio Capital Management to accelerate global expansion and technology development. The funding will support next‑generation remote patient monitoring, proprietary sleep diagnostic devices, and comparative clinical studies. CEO Len Liptak emphasized that the partnership validates ProSomnus’s mission to deliver data‑driven, patient‑preferred OSA therapies. CFO Jason Orchard noted the investment will optimize infrastructure and enhance patient outcomes. Catalio’s Dr. Nicholas von Guionneau joins as Board Observer, highlighting ProSomnus’s leadership in connected, precision sleep solutions. (Link)
  3. Dallas-Based SpendRule Exits Stealth with $2M Seed Round from Abundant Venture Partners, MemorialCare Innovation Fund, and Zeal Capital Partners to Automate AI-Powered Contract Compliance and Invoice Validation for Hospitals like OSF HealthCare, Kettering Health, MemorialCare, and MUSC Health SpendRule, founded by Chris Heckler and Joseph Akintolayo, automates contract compliance and invoice validation for health systems. Its AI software checks purchased services invoices against contract terms pre-payment, integrating seamlessly with ERP systems, contract management, and accounts payable workflows. The funding will expand the team and advance AI infrastructure. Backed by Abundant Venture Partners—a Chicago VC focused on healthcare innovation with a network of 22+ provider organizations—SpendRule serves major clients including OSF HealthCare, Kettering Health, MemorialCare, and MUSC Health. (Link)
  4. Covetrus and MWI Animal Health Strike $3.5 Billion Merger Deal, Forming Tech-Enhanced Platform with Cencora Retaining Major Stake Covetrus and MWI Animal Health announced a blockbuster $3.5 billion merger on February 18, creating a unified “comprehensive animal health platform.” MWI’s owners, Cencora, will receive $1.25 billion in cash and equity stakes, retaining a 34.3% share in the new entity. Leaders hailed the deal for blending MWI’s supply chain prowess and customer ties in companion and production animal sectors with Covetrus’ tech-driven veterinary solutions. The combo promises enhanced logistics, cost savings, broader customer reach—from vets and producers to pet owners—and accelerated innovation to make animal care more affordable and accessible. (Link)
  5. Grail’s Galleri Multi-Cancer Early Detection Blood Test Misses Primary Endpoints in Large Screening Trial Grail’s Galleri multi-cancer early detection blood test recently failed to meet its primary endpoints in a large clinical screening study, raising doubts about its effectiveness as a broad population screening tool. Following the release of these results, the company’s stock experienced a significant decline as investors reassessed commercial prospects. The data suggested lower than expected sensitivity for detecting certain cancers, which could complicate regulatory and reimbursement pathways. The outcome underscores ongoing challenges for next-generation liquid biopsy tests in proving clinical utility at scale. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Feb 16th, 2026

LECO_Weekly-Healthcare-News_2.16.2026Download
  1. Eli Lilly (NYSE: LLY) acquires Orna Therapeutics for up to $2.4 billion to enter in vivo CAR-T therapy market The all-cash acquisition gives Lilly access to Orna’s engineered circular RNA platform combined with lipid nanoparticles to generate cell therapies within patients’ bodies. Orna’s lead asset, ORN-252, targets CD19 for B-cell-driven autoimmune diseases and is described as clinical trial-ready. Founded in 2021 with technology from MIT researchers Alex Wesselhoeft, Ph.D. and Professor Dan Anderson, Ph.D., Massachusetts-based Orna raised $321 million across seed and Series B rounds and established collaborations with Merck & Co. and Vertex. The platform aims to deliver more durable therapeutic protein expression than current RNA or cell therapy approaches, addressing complexity and cost challenges of ex vivo CAR-T therapies. (Link)
  2. Sanofi (NASD: SNY) completes acquisition of Dynavax Technologies at $15.50 per share The acquisition includes Dynavax’s adult hepatitis B vaccine HEPLISAV-B, currently marketed in the U.S. with a differentiated two-dose regimen over one month, along with shingles vaccine candidate Z-1018 in phase 1/2 studies and additional vaccine pipeline projects. The tender offer expired on February 9, 2026, and Sanofi accepted all validly tendered shares on February 10, 2026. Following the merger under Delaware General Corporation Law Section 251(h), Dynavax became an indirect, wholly owned subsidiary of Sanofi. The transaction augments Sanofi’s adult immunization presence by combining Dynavax’s vaccines with Sanofi’s commercial reach, global scale, and development capabilities. (Link)
  3. Waters Corporation (NYSE: WAT) completes combination with BD’s Biosciences & Diagnostic Solutions (NYSE: BDX) businesses through Reverse Morris Trust transaction, forming global life sciences and diagnostics leader The transaction creates a combined company with Waters shareholders holding 60.8% and BD shareholders owning 39.2% on a fully diluted basis. Waters has established four divisions: Waters Analytical Sciences (separations science and mass spectrometry), Waters Biosciences (flow cytometry and single cell multiomics), Waters Advanced Diagnostics (microbiology, molecular, and multiplex testing), and Waters Materials Sciences (thermal analysis and rheology). The company also appointed Dr. Claire M. Fraser, an internationally recognized genome scientist and former Director of The Institute for Genome Sciences at University of Maryland, to its Board of Directors, expanding the board to 11 members. (Link)
  4. Harbor Health acquires Rippl with continued backing from Kin Ventures, ARCH Venture Partners, General Catalyst, GV, F-Prime Capital, JSL Health and Mass General Brigham Ventures to expand dementia support services The acquisition expands Harbor Health’s condition-focused care pathways into dementia management and extends its geographic footprint into Florida, building on its 2025 purchase of 32 VillageMD clinics. Rippl’s dementia care platform helps seniors remain at home while avoiding unnecessary emergency department visits, hospitalizations, and post-acute care through early identification of medical and behavioral issues. The program will be available at Harbor Health and VillageMD locations in Austin, Dallas, San Antonio, and El Paso for Medicare Advantage members and traditional Medicare beneficiaries through CMS’ GUIDE program, supporting Harbor Health’s proactive, integrated care-and-coverage model. (Link)
  5. Patient Square Capital signs definitive agreement to acquire Paradigm from OMERS Private Equity The transaction reflects Patient Square’s long-standing relationship with Paradigm’s leadership and confidence in the company’s ability to manage complex, high-acuity cases while delivering measurable cost savings and improved outcomes. Walnut Creek-based Paradigm is a specialty care management organization focused on individuals with complex injuries and diagnoses, with growing leadership in payment integrity, home health, and network services across workers’ compensation and healthcare payer sectors. The acquisition marks the successful conclusion of Paradigm’s partnership with OMERS Private Equity. Patient Square will support Paradigm’s expansion beyond its proven workers’ compensation model into the broader healthcare landscape under CEO John S. Watts, Jr.’s leadership. (Link)
  6. ReviveHealth acquires Doseform, via its financial sponsor Eir Partners, to integrate AI driven automation and patient engagement platform across pharmacy operations The acquisition establishes Doseform as the patient management system for Revive’s Pharmacy Centers of Excellence, with deployment planned across all pharmacy locations. Founded in 2021, Doseform uses AI-driven two-way messaging to streamline prescription workflows, payments, and patient communications through automated SMS and mobile links. The platform enables patients to view prescriptions, confirm orders, complete intake forms, and submit payments directly from phones without portals or apps. It addresses routine questions about refills, copays, and order status through AI-enabled chat, reducing inbound call volume and allowing pharmacy teams to focus on higher-value services while supporting rapid growth and operational efficiency. (Link)
  7. Traumasoft acquires Huly, via its financial sponsor Serent Capital, to advance AI strategy for EMS industry Huly will retain its independent brand, leadership team, and R&D operations under Founder and CEO Nidhish Dhru, remaining accessible to EMS agencies regardless of their technology stack. The AI-native platform automates time-intensive administrative processes across pre-billing, Quality Assurance/Quality Improvement, and payroll workflows. Agencies using Huly report first-time billing rejections dropping from approximately 60% to near 10%, along with improved cash flow, accuracy, and staff productivity. Traumasoft customers will benefit from tightly integrated workflows connecting HMS, billing, QA/QI, and AI-driven automation. The structure allows Huly to innovate across the EMS ecosystem while delivering value within Traumasoft’s platform. (Link)
  8. Humana Health’s (NYSE: HUM) CenterWell completes acquisition of MaxHealth from Arsenal Capital Partners to expand senior-focused primary care network The Florida-based primary care organization operates 54 owned primary care clinics, 4 owned specialty/ancillary clinics, and 24 downstream affiliate clinics throughout West and South Florida, serving more than 120,000 patients including over 80,000 in value-based care programs. MaxHealth will now be affiliated with CenterWell Senior Primary Care, the nation’s largest senior-focused, value-based primary care provider, expanding CenterWell’s reach into new key markets. MaxHealth will continue operating under CEO Michelle Leslie’s leadership. (Link)
  9. Abound Health acquires Pro Care Unlimited, via its financial sponsors Housatonic Partners, Peterson Partners, The Cambria Group, Trilogy Search Partners, WSC & Company, Relay Investments, Aspect Investors and Endurance Search Partners, to expand intellectual and developmental disability services into Michigan Effective January 1, 2026, Michigan-based Pro Care Unlimited joined Abound Health while retaining its current name and leadership. Pro Care will gain access to Abound’s infrastructure, clinical oversight, leadership development programs, direct care worker recognition initiatives, emergency assistance through Abound Cares, and scholarships and training resources. Founded over 20 years ago in North Carolina, Abound Health now serves more than 6,000 individuals across North Carolina, Pennsylvania, New Jersey, and Michigan with over 7,500 team members. The acquisition aims to build one of Michigan’s most robust IDD networks. (Link)
  10. Natus Sensory acquires TheraB Medical to expand neonatal phototherapy portfolio with FDA-cleared wearable technology The acquisition adds TheraB Medical’s SnugLit™, the first FDA-cleared wearable phototherapy system designed as a single swaddle-style garment for treating neonatal jaundice, to Natus Sensory’s newborn care portfolio. SnugLit received FDA 510(k) clearance in January 2026 and enables infants to remain close to caregivers during treatment, supporting bonding and family-integrated care models. The wearable device complements Natus Sensory’s existing hospital-based phototherapy solutions, providing clinicians greater flexibility to tailor treatment across hospital and home-care settings. Natus Sensory’s global presence and established hospital relationships will enable access to innovative technology for families and clinicians. (Link)
  11. HealthMark Group acquires Purview, via its financial sponsors Aspect Investors, WSC & Company, Ridgemont Equity Partners, TA Associates Management, Saltoun Capital Partners and BaseFour, to expand digital access to medical imaging and modernize image sharing infrastructure The acquisition addresses the healthcare industry’s persistent reliance on physical discs for medical image sharing, with approximately two-thirds of radiological images still distributed this way. Purview’s cloud-based platform simplifies ingestion, analysis, and sharing of medical imaging data, providing quick and secure access to imaging records regardless of care delivery location. Trusted by numerous academic medical centers and five of the top ten children’s hospitals, Purview will integrate into HealthMark’s clinical data exchange solution to provide complete, timely access to medical imaging across regions, institutions, and care settings, accelerating care delivery and improving patient outcomes for authorized recipients. (Link)

Venture and Other News  

  1. Talkiatry raises oversubscribed $210M Series D led by Perceptive Advisors with Sofina, Andreessen Horowitz and Left Lane Capital to expand telepsychiatry services The New York City-based company will use proceeds to build technology and expand services across the mental health acuity spectrum, including lower-acuity offerings like couples therapy and future higher-acuity services such as intensive outpatient support. Talkiatry directly employs over 800 full-time psychiatrists and is in-network with more than 100 insurers covering over 170 million lives, delivering 3 million patient visits to date. The company’s Mindshare Partner Program partners with over one-third of the country’s top 20 health systems, enabling patient referrals while integrating with existing EMR systems and workflows, achieving cost reductions up to $700 per member per month. (Link)
  2. Solace Health raises $130M Series C led by IVP with Menlo Ventures, SignalFire, Torch Capital, Inspired Capital, and RiverPark Ventures to scale patient advocacy platform at $1B valuation Founded in 2022, Solace Health will use proceeds to expand its national advocate network beyond 2,000 existing advocates, invest in platform and clinical research, and deepen payer and provider partnerships to embed advocacy earlier in patient journeys. The digital platform matches Medicare and Medicare Advantage patients with trained healthcare advocates who coordinate care, manage appointment logistics, attend appointments, reduce medical bills, organize documents, manage insurance appeals, and oversee care transitions. Serving over 20,000 patients monthly, 98% report better outcomes, with 95% paying no out-of-pocket costs for services. (Link)
  3. Garner Health raises $118M Series D led by Kleiner Perkins with Redpoint, Maverick, Kaiser Permanente Ventures, Mercy and Plus Capital to scale AI-driven care navigation platform at $1.35B valuation The New York-based company will use proceeds to expand its proprietary doctor ranking platform, scale AI-driven navigation and appointment booking capabilities, and grow its team. Garner leverages medical data covering over 320 million patient records to identify high-performing doctors who follow latest research and avoid unnecessary procedures, showing top providers have 75% lower complication and mortality rates. The platform acts as a financial administrator layering atop existing health plans, covering out-of-pocket costs when employees see top providers. This results in employees paying 80% less while employers achieve 12% total healthcare cost reduction, serving over 2.5 million members across 700 clients. (Link)
  4. Anterior raises $40M funding round led by FPV and Kinnevik with NEA and Sequoia Capital to scale AI platform for health insurers The round brings Anterior’s total funding to $64 million as the company expands its clinician-led AI platform that supports health plans with prior authorization, payment integrity, and risk adjustment workflows. Founded by physician and former Google product leader Dr. Abdel Mahmoud, Anterior deploys AI directly into clinical workflows with a team comprising 40% clinicians who contribute to the codebase. The company has deployed across major U.S. health plans including Geisinger Health Plan, built strategic integrations with HealthEdge, and supports organizations covering 50 million lives through its Forward Deployed Clinician model that pairs advanced technology with embedded clinical expertise. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Feb 9th, 2026

LECO_Weekly-Healthcare-News_02-09-2026Download
  1. Weight-loss drugs to compete on biggest stage with Super Bowl ads (Link)
    • Official NFL Super Bowl Commercials 2026 – All Commercials (Link)
      • Novo Nordisk (Wegovy): Celebrity-filled oral weight-loss pill promo. (Link)
      • Hims & Hers: Highlights wealth-health inequality gap. (Link)
      • Ro: Serena Williams promotes GLP-1 telehealth. (Link)
      • Novartis: Encourages prostate cancer blood test screening. (Link)
      • Boehringer Ingelheim: Raises awareness for kidney disease screening. (Link)
  2. TrumpRx launches with AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer to offer discounted drugs for U.S. cash‑paying patients under Most favoured Nation policy
    The TrumpRx direct‑to‑consumer platform introduces over 40 discounted prescription drugs to help uninsured or cash‑paying U.S. patients access more affordable treatments. The initiative, backed by the first five pharmaceutical companies signing pricing deals under the Most Favoured Nation policy, includes major blockbusters such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, both offered at significantly reduced prices. Additional products include insulin, fertility therapies, and inhalers from Pfizer and others. Sixteen global drugmakers are expected to join the platform, which aims to align U.S. medication prices with international standards while reshaping the domestic pricing landscape and consumer access dynamics. (Link)
  3. Takeda deepens AI drug discovery push with $1.7 billion Iambic deal
    Takeda Pharmaceutical enters multi-year AI drug discovery collaboration with Iambic Therapeutics worth more than $1.7 billion to accelerate small-molecule development in oncology, inflammation, and gastrointestinal diseases. The partnership underscores Takeda’s push to fully integrate AI into its R&D engine, following prior deals like its Nabla Bio collaboration, as big pharma bets on AI to speed discovery, reduce costs, and target complex diseases more precisely. Iambic, a San Diego-based biotech with a growing pipeline of AI-discovered candidates, gains validation and funding to expand its platform amid surging interest in AI-driven drug design. (Link)
  4. Once Upon a Farm (NYSE: OFRM) raises $198M in NYSE IPO backed by Goldman Sachs and J.P. Morgan to expand organic children’s food business co-founded by Jennifer Garner
    The company’s public debut marks a major milestone for the organic children’s food brand, offering 11 million shares at $18 each. Founded by Cassandra Curtis and Ari Raz in 2015 and later joined by Jennifer Garner and John Foraker, Once Upon a Farm produces cold-pressed pouches, frozen meals, and oat bars made from responsibly sourced fruits and vegetables. The IPO strengthens its ability to meet rising consumer demand for clean, nutritious food products while amplifying its retail presence. Despite global supply challenges, the company aims to grow amid increasing momentum in the health-conscious food and beverage market. (Link)
  5. TenetHealthcare (NYSE: THC) receives $1.9B from CommonSpirit to regain full ownership of Conifer Health Solutions
    Under the agreement, CommonSpirit will pay Tenet Healthcare $1.9 billion in instalments over three years to sell its 23.8% equity stake in Conifer Health Solutions, Tenet’s revenue cycle management subsidiary. The transaction, retroactive to January 1, 2026, also includes a $540 million payment from Conifer to eliminate CommonSpirit’s capital account and finalize the stake redemption. Conifer will continue providing services to CommonSpirit through the end of 2026 while onboarding new clients. Tenet expects the move to strengthen its financial outlook, citing operational efficiency, revenue growth, and strategic alignment as key drivers for sustaining profitability and future expansion. (Link)
  6. PrimeGen US to merge with DT Cloud Star Acquisition Corporation (NASD: DTSQ) in a $1.5B business combination to accelerate stem cell and exosome therapy development
    The merger will position PrimeGen US for public market access and expanded funding to advance its regenerative medicine portfolio. The company’s lead program centers on its proprietary Triple Activated Mesenchymal Stem Cell (MSC) platform, being developed as a treatment for acute alcoholic hepatitis and other liver-related conditions. The deal, expected to close in the second half of 2026 pending shareholder and regulatory approvals, will support clinical progression, regulatory submissions, and potential commercialization. PrimeGen’s leadership emphasized that the transaction marks a major step toward scaling its two-decade foundation in stem cell innovation into transformative therapies for critical diseases. (Link)
  7. Eikon Therapeutics (NASD: EIKN) raises $381M in upsized Nasdaq IPO, the largest biotech listing since 2024, led by former Merck executive Roger Perlmutter
    Proceeds from the public offering will fund the clinical advancement of Eikon’s oncology pipeline, notably EIK1001, a toll-like receptor 7/8 agonist currently studied with Keytruda in melanoma and lung cancer. Additional programs include PARP1 inhibitors EIK1003 and EIK1004—targeting ovarian, breast, prostate, and pancreatic cancers—and EIK1005, a WRN helicase inhibitor in early-stage development for solid tumours. The company, founded in 2021, continues to build momentum on its immunotherapy and precision oncology strategy, backed by prior multimillion-dollar financing rounds that have supported rapid progression from preclinical research to multiple active phase 1/2 and 2/3 trials across critical cancer indications. (Link)
  8. SpyGlass Pharma (NASD: SGP) launches $150M Nasdaq IPO for advancing long-acting eye drug delivery innovation
    Funds from the IPO will advance SpyGlass Pharma’s lead candidate, the Bimatoprost Drug Pad-IOL System, a long-acting intraocular lens designed to deliver sustained treatment for glaucoma and ocular hypertension. The device, implanted during cataract surgery, provides years of drug release, potentially eliminating the need for daily eye drops. Proceeds will support two phase 3 clinical trials already underway and a potential commercial rollout upon successful results. Early studies demonstrated significant intraocular pressure reduction, affirming the platform’s promise. SpyGlass joins a wave of biotech companies reinvigorating the IPO market as investors renew interest in ophthalmic and drug-delivery innovations. (Link)
  9. Agomab Therapeutics (NASD: AGMB) raises $200M in Nasdaq IPO to support development of ALK5 inhibitors for fibrostenosing Crohn’s disease and pulmonary fibrosis
    Proceeds from the IPO will fund Agomab Therapeutics’ next-stage clinical programs, including a global phase 2b trial for ontunisertib, its leading oral ALK5 inhibitor targeting fibro stenosing Crohn’s disease. The company also plans to advance AGMB‑447, another ALK5 inhibitor in phase 1 studies for idiopathic pulmonary fibrosis, toward midstage development. Both candidates were obtained through Agomab’s 2021 acquisition of Origo Biopharma. The IPO proceeds will also bolster operational growth and global research capabilities as Agomab pursues fibrosis-modifying therapies aimed at halting disease progression in patients with chronic intestinal and respiratory conditions. (Link)
  10. Veradermics (NYSE: MANE) raises $256M in NYSE IPO with investment interest from Eli Lilly and Wellington Management to advance oral minoxidil hair regrowth therapy
    The Connecticut-based biotech’s IPO marks a strong debut, with shares more than doubling in their first trading session. Veradermics focuses on developing VDPHL01, an extended-release oral version of minoxidil, intended to overcome limitations of topical Rogaine. The funds will support phase 3 trials evaluating its efficacy in treating pattern hair loss. Eli Lilly expressed interest in acquiring up to 4.9% of issued shares, while Wellington Management indicated plans to invest up to $30 million. The company seeks to capture a major share of the expanding global hair loss market and lead innovation in convenient, effective hair restoration therapies. (Link)
  11. Kaiser Permanente and Renown Health complete joint venture to jointly own Hometown Health and expand integrated care access in northern Nevada
    The finalized partnership marks Kaiser Permanente’s entry into northern Nevada through the joint ownership of Hometown Health and collaboration with Renown Health’s established provider network. The venture aims to expand access to affordable, value-based care while integrating insurance coverage and clinical delivery across the region. Kaiser Permanente will open two new medical centers in 2026, adding to its existing Reno location, and plans to introduce its digital health platform and in-house pharmacy network by 2027. The collaboration combines Kaiser Permanente’s national capabilities with Renown’s strong local presence to enhance clinical outcomes and improve patient experience across northern Nevada. (Link)
  12. NuvemRx acquires 340B referral technology company par8o from R1 RCM, via its financial sponsors Parthenon Capital Partners and Rainmaker Strategic Capital to enhance specialty care coordination and expand pharmacy network capabilities
    The acquisition integrates par8o’s AI-powered referral capture technology with NuvemRx’s pharmacy management and third-party administration services, enabling covered entities to more efficiently manage 340B referrals and specialty prescriptions. The combined platform now supports over 800 covered entities and impacts more than 70 million patients nationwide. By automating up to 85% of the referral and eligibility process, the integration reduces administrative burdens, enhances compliance, and increases savings opportunities for safety-net providers. The move strengthens NuvemRx’s mission to simplify pharmacy operations, expand access to affordable care, and improve coordination across community health and specialty care networks.  (Link)
  13. MedRisk to acquire Horizon Casualty Services PPO Network business from Horizon Mutual Holdings, via its financial sponsors CVC Capital Partners and The Carlyle Group to expand managed care capabilities in workers’ compensation and auto casualty markets
    The acquisition enhances MedRisk’s reach and service offerings within the casualty claims industry by integrating Horizon Casualty Services’ PPO Network business. The move aligns with MedRisk’s strategy to deliver improved patient outcomes, streamlined claims management, and optimized payment solutions. The integration supports faster recovery times, smarter spending, and enhanced client value while reinforcing the company’s commitment to innovation and superior service across workers’ compensation and auto casualty markets. (Link)
  14. Coloplast discloses definitive agreement for Uramedica acquisition in Q1 2025/26 earnings Report
    Coloplast US signs definitive merger agreement to acquire all outstanding shares of Uromedica, a privately held US medtech company specializing in minimally invasive treatments for stress urinary incontinence, making Uromedica a wholly owned subsidiary. The acquisition is expected to close in February 2026, subject to customary closing conditions and requisite Uromedica shareholder approval. The move aligns with Coloplast’s strategy to bolster growth in urology through targeted additions, amid strong organic performance in the division. (Link)
  15. Konovo acquires Rare Patient Voice, via its financial sponsors Bain Capital Credit, Frazier Healthcare Partners, GV Investment Managers and Leavitt Equity Partners to expand access to 200,000+ patients and caregivers The acquisition strengthens Konovo’s healthcare intelligence platform by combining its data-driven capabilities and healthcare provider network with Rare Patient Voice’s extensive, community-driven database of patients and caregivers. This integration enhances the ability of researchers to access hard-to-reach populations and capture real-world patient insights across therapeutic areas. Konovo plans to scale these efforts globally while integrating patient and clinician perspectives into unified, technology-enabled research solutions. The partnership drives faster, more informed decision-making for healthcare organizations advancing innovation in complex diseases. (Link)
  16. RadNet (NASD: RDNT) acquires Northwest Radiology in Indiana, adding six imaging centers to expand Midwest footprint and enhance AI-powered diagnostic services
    The acquisition marks RadNet’s entry into Indiana, extending its national imaging network into the Midwest through six outpatient centers in the Indianapolis region. Northwest Radiology’s 18 radiologists will continue providing contracted professional services, ensuring continuity and maintaining strong local physician relationships. The integration will leverage RadNet’s advanced imaging technologies and AI-driven workflows to improve early disease detection and overall population health management. With the addition expected to generate approximately $18 million in annual revenue, RadNet aims to expand its proactive diagnostic approach while strengthening patient access to high-quality, cost-effective imaging care across Indiana. (Link)
  17. Nautic Partners completes growth investment in KabaFusion as Novo Holdings exits, supporting expansion of home infusion care services
    The partnership marks a new phase for KabaFusion, a national leader in home and alternate site infusion therapy. With operations covering 45 states through 33 pharmacies and 21 infusion suites, the company will leverage Nautic Partners’ investment to accelerate its growth and innovation initiatives. KabaFusion’s management team, which remains significant investors, will continue leading the organization to enhance patient access and clinical excellence. The investment underscores Nautic’s strategy of backing mission-driven healthcare providers delivering high-quality, patient-centered care, marking the exit of Novo Holdings following its successful tenure supporting KabaFusion’s nationwide expansion. (Link)
  18. Black Pearl Equities Announces Intention to Commence Tender Offer to Acquire Selectis Health, Inc.
    Black Pearl Equities, LLC announces intention to commence an all-cash tender offer to acquire all issued and outstanding shares of common stock of Selectis Health, Inc. (OTC: GBCS) at $4.00 per share. The proposed transaction is subject to negotiation and execution of definitive transaction documentation as well as customary closing conditions.  Selectis Health operates skilled nursing and transitional care facilities, and this unsolicited proposal follows the company’s recent asset sales and operational streamlining efforts. (Link)
  19. Vanderbilt Health acquires Tennova’s Clarksville Hospital, Tennova ER-Sango, and physician clinics from Community Health Systems to expand regional care network
    The acquisition expands Vanderbilt Health’s footprint across Middle Tennessee, adding the 270-bed Clarksville hospital, freestanding Sango ER, and multiple physician practices to its growing regional system. Vanderbilt Clarksville Hospital (VCH) will serve as a hub for expanded emergency, surgical, and specialty services, with new paediatric and adult programs planned in collaboration with Monroe Carell Jr. Children’s Hospital. The integration brings nearly 1,100 staff and over 30 physicians into Vanderbilt’s network, reinforcing its commitment to delivering high-quality, community-based care. The move marks Vanderbilt’s fourth regional hospital acquisition, extending its reach beyond Nashville and strengthening access to advanced health services statewide. (Link)

Venture and Other News  

  1. Midi Health closes $100M Series D in Goodwater Capital–led round with Foresite Capital, Serena Ventures, Advance Venture Partners, GV, Emerson Collective, SemperVirens and McKesson Ventures to scale national women’s health platform
    The virtual women’s health clinic now serves over 230,000 patients across 50 states through a network of 500 providers, treating 25,000 patients weekly. Founded in 2021 to address perimenopause and menopause care, the company is expanding into metabolic health, weight management, and musculoskeletal health. The platform uses AI-powered tools for chart analysis, scheduling, and care protocols while offering insurance-backed services reaching 45 million women. The company reports improved screening adherence rates and up to 13% lower total cost of care, with plans to expand Medicare and Medicaid coverage. (Link)
  2. Chamber raises $60M Series A led by Frist Cressey Ventures with General Catalyst, AlleyCorp, American Family Ventures, Company Ventures, Optum Ventures, Healthworx Ventures and Black Opal Ventures to scale cardiology value-based care
    The funding will accelerate Chamber’s mission to modernize cardiovascular care through value-based models that improve outcomes while lowering costs. The company’s platform integrates AI-driven insights to help cardiologists identify high-risk patients, close care gaps, and streamline workflows within existing systems. Partnering with both payers and practices, Chamber supports data-informed, proactive management of chronic heart disease. With more than 500 cardiologists across seven states already on its network, the company plans to expand its national footprint and strengthen partnerships with health plans. The investment underscores growing momentum behind value-based innovations addressing cardiovascular care delivery and patient experience. (Link)
  3. Alaffia Health raises $55M Series B led by Transformation Capital with FirstMark Capital, Tau Ventures, and Twine Ventures to expand AI-driven health plan operations
    The latest funding round accelerates Alaffia Health’s mission to reduce healthcare’s $570 billion in administrative waste through advanced, clinically informed AI for health plan claims management. The company’s platform combines physician oversight with agentic AI to enhance accuracy, speed reviews, and achieve measurable cost savings for national and regional payers. Delivering over 20% savings on high-cost claims and fivefold ROI, Alaffia plans to use the new capital for R&D, product innovation, and scaling adoption across the healthcare ecosystem. The investment supports ongoing efforts to create transparent, compliant, and efficient claims infrastructure that strengthens affordability and systemwide operational performance. (Link)
  4. Third Arc Bio raises $52M Series A extension led by Andreessen Horowitz with Omega Funds, Goldman Sachs Alternatives, BVF Partners, T. Rowe Price, Galapagos NV, AbbVie Ventures and Alderline Group to advance oncology and immunology pipeline
    The funding strengthens Third Arc Bio’s efforts to expand its multifunctional antibody programs in oncology and immunology. The capital will accelerate clinical development of the company’s lead asset, ARC101—a bispecific T cell engager targeting CLDN6 in advanced solid tumours—while advancing next-generation inflammation and immune modulation candidates toward human trials. Leveraging its ARCTag (Tethered Agonist) platform, Third Arc Bio aims to localize immune activity precisely at disease sites, enhancing efficacy and reducing systemic toxicity. Supported by a seasoned scientific team, the company continues to validate its platform approach to develop targeted biologics addressing major unmet medical needs. (Link)

Market Rumours

  1. Seed Health reportedly retains Centerview Partners to explore potential sale amid strong financial performance
    Seed Health has reportedly hired Centerview Partners to advise on a potential sale as it attracts strong interest from strategic and private equity buyers. Generating about $200 million in revenue and over $50 million in EBITDA, the company aims to leverage rising global demand for premium probiotics and wellness products.
  2. HHAeXchange reportedly explores sale with Centerview Partners advising; backed by Cressey & Company and Hg Capital
    The company, generating about $100 million in recurring revenue, develops software that streamlines compliance and operations for Medicaid homecare providers. Having expanded through acquisitions of Sandata Technologies, Generations Homecare Systems, and Cashe Software, it reflects growing investor interest in post‑acute healthcare tech consolidation during ongoing strategic review discussions.
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jan 26th, 2026

LECO_Weekly-Healthcare-News_1-26-2026Download
  1. Winter Storm Fern Cripples Half the Country This Weekend
    • CNBC: $100B expected economic loss and damages from storm (Link) 
    • CNBC: Transportation Sec. Duffy says air travel will return to normal by Wednesday (Link) 
    • The Weather Channel: Winter Storm Fern Turns Deadly In Louisiana, Outages For Hundreds Of Thousands Vulnerable To Ice, Snow (Link) 
    • National Public Radio: As the winter storm rages, here’s what to know in your state(Link)
  2. GSK (NYSE:GSK) pays $2.2B to acquire Rapt Therapeutics (NASD:RAPT) and Food Allergy Antibody Ozureprubart GSK is acquiring Rapt Therapeutics for $58 per share, gaining global (ex‑China) rights to ozureprubart, an extended‑half‑life anti‑IgE antibody being studied as a 12‑weekly prophylactic treatment for food allergies. Unlike currently approved IgE inhibitors that require injections every 2–4 weeks, ozureprubart aims to offer sustained protection with less frequent dosing while targeting the same validated pathway as Xolair. The deal follows Rapt’s strategic pivot away from its CCR4 inhibitor program after clinical setbacks and positions ozureprubart for phase 2 readout in 2027 and a planned phase 3 program, backed by GSK’s global development and commercialization infrastructure. (Link)
  3. BioCryst (NASD: BCRX) acquires Astria Therapeutics (NASD:ATXS) in $700M deal to Build Comprehensive Hereditary Angioedema Treatment Platform The transaction adds Navenibart, a long-acting plasma kallikrein inhibitor in Phase 3, which is being developed as a prophylactic HAE treatment with every‑three or every‑six month dosing to improve patient convenience and attack control. BioCryst now pairs its existing oral therapy ORLADEYO with a potential injectable option to give clinicians more flexibility in tailoring care. The deal also brings STAR0310, an early atopic dermatitis program for which strategic options will be explored, and augments BioCryst’s leadership with Astria’s former CEO joining the board and a senior development leader taking charge of technical operations. (Link)
  4. Georgia ProtonCare Center, Inc. Files Chapter 11 to Facilitate Competitive Sale Process and Enters Into Asset Purchase Agreement With Emory Healthcare Georgia ProtonCare Center (GPCC), owner of Georgia’s only proton therapy cancer treatment facility in Midtown Atlanta, has filed for Chapter 11 bankruptcy to facilitate a court-supervised sale process and ensure uninterrupted patient care. The company has signed an asset purchase agreement with Emory Healthcare (via Emory University Hospital Midtown) as the stalking horse bidder to acquire substantially all assets, with Emory clinicians already providing daily treatment at the center. GPCC aims to complete the competitive sale by Q2 2026, prioritizing seamless continuation of precision proton therapy services for cancer patients while operations continue as usual under court-approved funding. (Link)
  5. KidsChoice Announces Majority Investment from Aquitaine Capital to Support Growth and Clinical Excellence KidsChoice, an Oklahoma-based provider of clinic-centered autism and pediatric therapy services including ABA, speech, and occupational therapy, has secured a majority investment from women-owned private equity firm Aquitaine Capital to fuel expansion, enhance clinical excellence, and strengthen infrastructure. The partnership supports thoughtful growth through new clinic openings, strategic M&A, and complementary offerings while prioritizing individualized, outcomes-driven care for children and families. (Link)
  6. Community Health Systems Sells Crestwood Medical Center to Huntsville Hospital Health System in $450M Deal The transaction will transfer Crestwood Medical Center, a 180‑bed acute care hospital in Huntsville, Alabama, along with a freestanding emergency department in Harvest and multiple clinics and outpatient assets, to a regional nonprofit operator. Crestwood’s roughly 1,000 employees will continue normal operations with no planned changes to services or medical staff privileges during the transition. Huntsville Hospital Health System, already a major 14‑hospital network across northern Alabama and southern Tennessee, views the deal as a way to better coordinate local care as Huntsville’s population rapidly grows, while the seller continues its strategy of divesting assets to strengthen its financial position. (Link)
  7. BioStem Technologies (OTC: BSEM) and BioTissue sign Up to $40M Surgical and Wound Care Asset DealThe transaction adds BioTissue’s Neox and Clarix placental- and umbilical‑tissue allograft product lines, along with a national direct and independent sales force and key group purchasing organization contracts, giving BioStem an immediate presence in hospital inpatient and outpatient settings. The acquired surgical and wound care assets, which generated about $29 million in 2025 sales, broaden BioStem’s chronic and acute wound care portfolio and create entry into high‑value segments such as burns and soft‑tissue repair. Deal terms include an upfront $15 million cash payment plus up to $25 million in potential regulatory and commercial milestone payments. (Link)
  8. Harmony Healthcare IT acquires Blue Elm, via its financial sponsor Novacap to build Comprehensive MEDITECH Data Lifecycle Platform Harmony Healthcare IT has acquired Blue Elm to offer MEDITECH hospitals a single, end-to-end partner for data extraction, conversion, migration, archiving, optimization, and real-time access across all MEDITECH versions. The combined capabilities help hospitals retire costly legacy systems, strengthen data integrity, and improve accessibility as they upgrade or transition EHR platforms. By unifying services under one organization and relying on U.S.-based resources instead of offshore outsourcing, the company aims to shorten complex project timelines, enhance security and quality, and better support hospitals under pressure to improve care quality while reducing operating costs. (Link)
  9. PhaseWell Research acquires Bio Behavioral Health Partner, via its financial sponsor Shore Capital Partners to expand Community-Based Neuropsychiatric Clinical Trials The acquisition will strengthen PhaseWell’s national network of community clinical research sites focused on neurologic and psychiatric disorders. The collaboration aims to broaden patient access to neuropsychiatric trials by leveraging BBH’s experience in community-based studies and PhaseWell’s nationwide platform and infrastructure. Together, the organizations plan to support sponsors with reliable patient enrolment, strong operational execution, and high-quality data while advancing next-generation CNS therapeutics across complex therapeutic areas, including oncology, cardiovascular/metabolic conditions, and dermatology. (Link)
  10. Pair Team acquires Town Square to Advance AI-Enabled Community Care for Medicare and Medicaid Beneficiaries The acquisition combines an AI-driven medical group with a social care coordination platform to better integrate clinical, behavioral, and social services for underserved populations. Technology will orchestrate complex, cross-setting care tasks so human teams can concentrate on clinical decisions, hands-on support, and relationships with patients and local organizations. Town Square’s founder will lead network expansion and community partnerships within the new structure, which emphasizes responsible AI, robust outcomes measurement, and investment in community-based infrastructure to extend whole-person care to people historically excluded from the healthcare system. (Link)
  11. Aspen Surgical expands Infection Prevention Portfolio with acquisition of Ruhof Healthcare, via its financial sponsors Linden and Audax Private Equity The buyer is adding enzymatic detergents, cleaning verification tools, and automated and manual instrument and endoscope reprocessing solutions to deepen its presence in operating rooms, sterile processing, and endoscopy settings. Ruhof’s portfolio, including Endozime detergents, ScopeValet single-use consumables, CleanRead ATP contamination monitoring, and instrument refurbishment services, will bolster the SPD360 Performance Solutions platform and complement existing brands such as Symmetry, Bookwalter, and Precept. The transaction covers all Ruhof operations, brands, and product lines, with integration set to begin immediately and no near-term disruption expected for customers, suppliers, or employees. (Link)
  12. TridentCare acquires DispatchHealth Imaging Unit to Grow National Portable Diagnostics Network The acquisition adds a multistate mobile X‑ray and ultrasound operation that serves patients at home, in post‑acute facilities, and in correctional settings, expanding TridentCare’s reach and capacity. By integrating these imaging teams and customers into its national infrastructure, TridentCare aims to speed response times, improve scheduling flexibility, and deliver more consistent service quality for clinicians and patients. DispatchHealth will continue focusing on providing complex care in the home and will coordinate imaging through technology and partnerships so patients and providers experience seamless, integrated services. (Link)
  13. Morris & Dickson Completes Transaction to Acquire Prodigy Health Morris & Dickson (M&D), the nation’s largest independent wholesale and specialty pharmaceutical distributor, has completed its acquisition of Prodigy Health, a specialty pharmaceutical distribution and services company focused on plasma-derived therapies. The transaction expands M&D’s specialty portfolio, broadens access to plasma therapies for hospitals, clinics, infusion centers, and alternative care sites nationwide, and strengthens its independent platform for manufacturers through a compliance-first approach. (Link)
  14. Main Post Partners and HomeWell Leadership acquire HomeWell Franchising to Accelerate Senior In‑Home Care Growth The deal pairs a national non‑medical home care franchisor with a private equity firm experienced in franchising and consumer service brands, aiming to fuel the next phase of expansion. The partners emphasize a “partnership, not ownership” philosophy, focusing on close collaboration with franchisees and caregivers to scale services while preserving mission and culture. Building on several years of rapid revenue growth and record franchise development, the company plans to invest in tools, resources, and support that help local agencies grow and better serve seniors and homebound individuals in their communities. (Link)

Venture and Other News  

  1. Zarminali Paediatrics raises $110M in Series A funding led by Healthier Capital, with participation from General Catalyst, K2 HealthVentures, and Boston Children’s Hospital to expand integrated paediatric care footprint The company will use the new capital to scale its proprietary tech platform, enter additional states and open de novo clinics while continuing to acquire established paediatric groups. Its model centers on a single branded multispecialty practice that co-locates clinics with urgent care, directly employing both paediatricians and specialists to coordinate care across the full continuum outside the hospital. Since launching in 2024, Zarminali has rapidly expanded to 28 clinics in eight states and plans at least 15 new sites in 2026, while laying groundwork for future value-based arrangements and building analytics to track clinician performance and patient outcomes. (Link)
  2. Mendra launches with $82M Series A co-led by OrbiMed, 8VC, and 5AM Ventures, with participation from Lux Capital and Wing VC to advance AI-driven rare disease therapeutics Mendra will use the oversubscribed financing to acquire and develop an initial portfolio of high-potential rare disease assets while applying AI to speed patient identification, trial enrollment and global market access. The company is built to modernize how rare disease medicines are developed and commercialized so they reach underserved patients more efficiently worldwide. A veteran leadership team with deep experience in rare disease drug development, global commercialization and AI—drawn from organizations such as BioMarin, Modis Therapeutics, Escient Pharmaceuticals, Palantir and Bayer—will guide strategy across asset selection, clinical execution and business development. (Link)
  3. AnswersNow raises $40M in Series B funding led by HealthQuest Capital, with participation from Left Lane Capital and Owl Ventures to Scale AI-Enabled Virtual Autism Therapy The company will use the new capital to expand its platform, double clinical headcount, add senior leaders and launch new service lines to meet surging demand for autism support. Its AI-driven model pairs families across the U.S. with Master’s- and PhD-level BCBAs for targeted, parent-mediated virtual ABA, cutting weekly therapy time from 30+ hours to about 4–5 while sustaining strong clinical gains. Outcomes data show high family-reported improvements, substantial cost savings for payors and a consistently strong satisfaction score, with forthcoming research in 2026 intended to further validate clinical and economic impact. (Link)
  4. BrightInsight secures $13M investment from Eclipse, General Catalyst, Insight Partners, Mayo Clinic and New Leaf Venture Partners to scale its AI-enabled medication adherence platform The company will deploy the capital to expand its AI-enabled persistence and adherence solutions, including a co-developed Patient App used across multiple diseases and therapies worldwide. By leveraging real-world data and advanced analytics, the platform targets chronically low adherence rates, aiming to predict churn and trigger personalized interventions that keep patients on therapy. BrightInsight reports strong patient engagement and one-year retention across programs and plans to deepen its product roadmap, broaden disease and biopharma partnerships, and add support for caregivers and nurse educators to ease pressure on health systems. (Link)
  5. McKinsey & Co Released their Annual Healthcare Outlook Report. To remain competitive in 2026 and beyond, healthcare leaders must improve performance, embrace technology and rethink traditional care models (Link)
  6. IPO Watchlist
    • Once Upon a Farm — Organic children’s food company co-founded by Jennifer Garner, is targeting a valuation of up to $764.4 million in its upcoming U.S. IPO on the NYSE under the ticker OFRM. (Link)
    • Kallyope — New York City-based biotechnology company specializing in novel therapeutics targeting the gut-brain axis and neural circuits.
    • Kardium — Vancouver area based medical device company focused on cardiac electrophysiology solutions; develops advanced catheter-based systems for the diagnosis and minimally invasive treatment of atrial fibrillation.
    • Tenpoint Therapeutics — London, UK-headquartered (with U.S. operations in Seattle and Irvine) ophthalmic biotechnology company dedicated to age-related vision restoration therapies.
    • Vensure Employer Solutions — Chandler, AZ -based professional employer organization (PEO) and provider of human capital management (HCM) technology serving the healthcare and broader employer ecosystem.
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jan 20th, 2026

LECO_Weekly-Healthcare-News_1-20-2026-1Download

Healthcare Weekly News and Deals – January 20th, 2026

  1. Takeaways from JPM 44th Annual Healthcare Conference 2026 The J.P. Morgan Healthcare Conference 2026 reflected a turn toward cautious yet genuineoptimism, fueled by policy tailwinds, AI’s proven impacts, and robust activity in strategiccollaborations and consolidations. AI emerged as a core driver, transitioning from hype tooperational ROI via agentic systems, closed-loop workflows, and ambient tools that enhancediscovery, delivery, and administrative efficiency. Federal efforts, including outreach on quality andaccess alongside high-impact innovation programs, underscore a proactive stance on reducingbarriers and accelerating progress. Cross-border dynamics and emerging modalities added to theforward-looking tone, signaling diversified growth opportunities. The event highlightedhealthcare’s trajectory for AI-enabled reinvention, with widespread alignment on prioritizingefficiency, transparency, execution, and adaptive strategies to navigate global and regulatory shifts.
    ● PitchBook Analyst Note: Takeaways from the J.P. Morgan Healthcare Conference (Link)
  2. OpenAI acquires Torch in ~$100M deal to accelerate ChatGPT Health OpenAI bought healthcare startup Torch, which aggregates users’ lab results, medications, visit notes, wearable data and consumer test reports into a unified health record, and will fold its team into efforts to expand ChatGPT Health. The year‑old Torch platform was built as a “medical memory” to unify fragmented records into a single context layer for AI. The acquisition follows OpenAI’s launch of ChatGPT Health, which links the chatbot to medical records and wellness apps for more personalized responses. OpenAI reports that about one in four of ChatGPT’s 800 million regular users asks at least one healthcare‑related question each week. (Link)
  3. Boston Scientific (NYSE: BSX) to acquire Penumbra (NYSE: PEN) in $14.5B cash-and-stock deal to expand vascular and neurovascular portfolio The transaction will be paid approximately 73% in cash and 27% in Boston Scientific stock, giving Penumbra shareholders the option of cash or shares subject to proration. Penumbra brings a portfolio that includes Lightning Bolt and Lightning Flash computer-assisted vacuum thrombectomy systems, peripheral embolization solutions, and neurovascular devices for stroke, aneurysms and other complex vascular conditions. Boston Scientific plans to fund the roughly $11 billion cash component with a mix of cash on hand and new debt and currently expects the deal to be modestly dilutive to adjusted earnings per share in the first full year after closing, turning neutral to accretive thereafter. (Link)
  4. Smith+Nephew (NYSE: SNN) to acquire Integrity Orthopaedics in Deal Worth up to $450M to Strengthen Rotator Cuff Portfolio The transaction includes an upfront $225 million cash payment plus up to $225 million in performance-based milestones over five years and is expected to close this month. Integrity Orthopaedics’ Tendon Seam rotator cuff repair system is designed with patented micro-anchors, individually locked stitches and an integrated implantation system to reduce re-tear rates and shorten procedures compared with traditional techniques, which can have structural failure rates of 20–40%. The acquisition supports Smith+Nephew’s RISE 2026 strategy and builds on prior shoulder investments, including the Regeneten bioinductive implant, Q-Fix Knotless All-Suture Anchor and the Aetos Shoulder System. (Link)
  5. Modella AI acquired by AstraZeneca (LON: AZN) to scale AI-driven oncology R&D globally The acquisition expands a multi-year collaboration by embedding Modella AI’s multimodal foundation models and agentic AI platform directly into AstraZeneca’s oncology research and development ecosystem. Modella AI’s technology, built at the intersection of pathology, clinical data and advanced generative AI, will be used to accelerate clinical development, enhance biomarker discovery and support data‑driven decision-making across AstraZeneca’s global oncology portfolio. AstraZeneca plans to deploy these AI agents and pathology foundation models to increase automation, scalability and consistency in data‑intensive workflows and to support the development of targeted therapeutics and companion diagnostics. (Link)
  6. Boston Scientific (NYSE: BSX) acquires Valencia Technologies to add eCoin ITNS device to urology portfolio The eCoin implantable tibial nerve stimulation system, placed under the skin near the ankle, is intended for urge urinary incontinence patients who do not tolerate or sufficiently benefit from conservative therapies, and received FDA clearance in 2022. In a pivotal study, 68% of treated patients achieved at least a 50% reduction in UUI episodes, underscoring its potential clinical impact. The transaction is expected to close in the first half of 2026, positioning Boston Scientific alongside Medtronic’s Altaviva device in the growing neuromodulation market for overactive bladder–related symptoms as the company continues to expand its pelvic health and neurology device franchises. (Link)
  7. Abbott (NYSE: ABT) and AtaCor collaborate on Next-Generation Extravascular ICD System The partners are combining an investigational parasternal extravascular defibrillation lead (Atala) with a minimally invasive implantable defibrillator platform intended to keep hardware outside the heart and vasculature, aiming to avoid complications such as vascular injury, lead fracture and infections. The Atala lead is placed through a rib space beside the sternum and is designed both to deliver defibrillation shocks and to direct pacing energy efficiently toward the heart. A pivotal ALARION EV Investigational Device Exemption study is planned for 2026 to evaluate the system as a potential new option for patients at high risk of life‑threatening arrhythmias. (Link)
  8. Hippocratic AI acquires Grove AI to build end-to-end agentic AI platform for biopharma and medtech The acquisition adds Grove AI’s agentic platform, which has supported over 10 million patient interactions and powered more than 50 phase 2 and 3 clinical trials, into Hippocratic AI’s life sciences division focused on regulated biopharma and MedTech use cases. Grove’s “Grace” agent and participant relationship management tools will be used to speed recruitment, improve screening and streamline trial operations across top global pharma partners, while Hippocratic extends agents into commercial, direct‑to‑patient and HCP engagement. The company has appointed Ahad Wahid, M.D., as president of life sciences and formed a senior advisory council to ensure safety, compliance and large‑scale deployment. (Link)
  9. Agentis Longevity acquires Arete Wellness, via its financial sponsor Shore Capital Partners to build national precision longevity and recovery platform The combined company will offer personalized, preventative programs that integrate advanced diagnostics, hormone and peptide therapies, IV recovery, performance medicine and lifestyle-focused support for high-performing clients such as professional athletes, entertainers and executives. Arete contributes a concierge recovery model delivered by a team of more than 45 traveling nurses and medical professionals, while Agentis brings precision-based longevity medicine focused on individualized, science-backed care. Leadership from both organizations position the deal as a way to expand geographic reach, increase accessibility and set a new standard for evidence-based performance longevity without disclosing financial terms. (Link)
  10. Apollo Care acquires eStrat, via its financial sponsor Flexpoint Ford to expand copay and patient access capabilities Apollo Care is adding eStrat’s copay program design and execution expertise to strengthen its technology-driven patient access, affordability and analytics platform. The combined offering aims to enable faster copay program launches, tighter integration between operations and analytics, and more seamless execution for pharmaceutical manufacturers across multiple therapeutic areas. Key eStrat team members are joining Apollo Care to ensure continuity for existing clients, with co-founder Trond Waerness stepping into a leadership role focused on patient affordability strategy. The companies say the deal will help manufacturers reduce complexity while improving access and affordability for patients. (Link)
  11. Zelis acquires Rivet, via its financial sponsors Bain Capital, Parthenon Capital Partners, Valspring Capital, BPEA Private Equity, Edison Partners, Bain Capital Ventures, Norwest, Ergo Partners, HarbourVest Partners and Mubadala Investment Company, to expand AI‑enabled revenue cycle analytics for healthcare payers and providers The deal adds Rivet’s analytics platform to Zelis’ existing payments technology, giving providers deeper visibility into claim payment patterns and denial trends via insight‑rich dashboards and workflow tools. By reducing transactional back‑and‑forth, payers can shift focus to collaborative efforts that improve first‑time claim success and cut down on costly rework. Executives from both companies frame the combination as a way to address mounting margin pressure, rising administrative costs and regulatory complexity while pushing the industry toward a more transparent, efficient financial experience for providers, payers and patients. (Link)
  12. Genomate Health acquires Oncompass Medicine to build integrated precision oncology platform in Europe The deal gives Genomate Health a long-standing European base with established logistics, clinical operations and market presence in personalized oncology, particularly in Hungary and across Europe. Oncompass, founded in 2003, brings two decades of experience in companion diagnostics and next-generation sequencing-based tumour profiling in routine clinical care. Scientific and clinical leadership will be driven by Genomate Health Founder and CSO Istvan Petak, who will also serve as Managing Director of Oncompass Medicine, as the combined organization deploys Genomate’s computational reasoning technology to turn complex molecular data into scalable, actionable treatment decisions for cancer patients worldwide. (Link)
  13. Behavioral Framework partners with Autism ETC, backed by Renovus Capital Partners, to expand autism care platform Autism ETC, which operates five ABA therapy and autism diagnostic clinics in Tennessee and Arizona, will join Behavioral Framework while retaining its leadership team and clinical staff to ensure continuity for families and employees. The combination is intended to extend high-quality, individualized autism services across both center-based and home-based models in the Southeast and beyond, supported by Behavioral Framework’s operational infrastructure, technology and growth resources. Both organizations emphasize preserving Autism ETC’s culture and clinical integrity while scaling access and investing in clinician development as part of Behavioral Framework’s broader growth strategy. (Link)
  14. EnableComp acquires Health Resources Optimization via its financial sponsors Primus Capital and Welsh, Carson, Anderson & Stowe to expand complex revenue recovery for hospitals The acquisition brings H/ROI’s clinical denials and post‑bill DRG validation expertise under EnableComp, strengthening its focus on complex claims, DRG downgrades and medical‑necessity denials. The combined organization aims to capture more hidden revenue for providers facing intense margin pressure and payer scrutiny by pairing seasoned clinical judgment with an AI‑driven revenue cycle platform. Serving over 1,000 hospitals and recovering $3 billion annually, EnableComp is integrating H/ROI to deliver deeper clinical insights, earlier underpayment detection and faster resolution of intricate denials so health systems can safeguard margins and improve financial stability while maintaining patient care. (Link)
  15. Solis Mammography acquires Women’s Center for Radiology, via its financial sponsors Madison Dearborn Partners and TowerBrook Capital Partners to expand Florida breast imaging footprint The deal adds two Orlando centers to Solis Mammography’s existing nine Florida locations in Gainesville, Fort Lauderdale and Miami, marking the company’s entry into the Orlando market and broadening its statewide presence in specialized breast health services. The combined organization aims to deliver comfortable, convenient and compassionate breast imaging to more patients across greater Florida while maintaining personalized, community-focused care. (Link)

Venture and Other News   

  1. JPM26: Anthropic launches Claude for Healthcare to Turbocharge AI efficiency at HealthSystems, Payers Anthropic introduced Claude for Healthcare at the J.P. Morgan Healthcare Conference (JPM26), providing purpose-built, HIPAA-ready AI tools for health systems, payers, providers, and hospitals to accelerate administrative and clinical workflows including prior authorization, clinical documentation, claims management, care coordination, regulatory submissions, and patient message triage. The platform connects Claude to key data sources such as the CMS Coverage Database (Local and National Coverage Determinations), ICD-10 codes, National Provider Identifier Registry, and PubMed (with over 35 million biomedical literature entries), enabling natural language querying, surfacing coverage differences, reducing claim denials, and supporting FHIR interoperability via Agent Skills. It builds on the October launch of Claude for Life Sciences with additional connectors for platforms like Medidata and ClinicalTrials.gov, while offering consumer-facing features like medical history summarization and health metric pattern detection through beta integrations with HealthEx, Function, Apple Health, and Android Health Connect. Emphasizing AI safety through its Constitutional AI approach, the tools aim to minimize hallucinations, ensure reproducible and cited results, and amplify human capabilities in highstakes, regulated healthcare environments, with early adoption by organizations including Banner Health, Stanford Healthcare, Novo Nordisk, Sanofi, AbbVie, and Genmab. (Link)
  2. OpenAI Invests in Merge Labs’ $250M Seed Led by OpenAI with Bain Capital, Interface Fund, Fifty Years and Gabe Newell to Advance Noninvasive Brain‑Computer Interfaces Merge Labs, a brain-computer interface “research lab” co-founded by Sam Altman and collaborators from Tools for Humanity, Forest Neurotech and Caltech, raised $250 million at an $850 million valuation to pursue non-invasive BCIs that link biological and artificial intelligence using molecules and deep-reaching modalities like ultrasound. The startup aims to extend human capabilities and restore or enhance brain function by interfacing with neurons at scale, with applications well beyond current medical BCI use cases. OpenAI plans to collaborate with Merge on foundation models and AI operating systems that interpret neural intent and work robustly with limited, noisy brain signals. (Link)
  3. Proxima raises $80M Seed Led by DCVC with NVentures, Braidwell, Roivant, AIX Ventures, Yosemite, Magnetic Ventures, Alexandria Venture Investments and Modi Ventures to Advance Proximity-Based Medicines The AI-native biotech, formerly VantAI, is developing proximity therapeutics that modulate protein–protein interactions, including modalities like molecular glues and PROTACs, to reach historically “undruggable” targets across oncology, immunology and other diseases. Its NeoLink data-generation technology and Neo AI model series generate proteome-scale structural data on protein complexes to enable rational design of proximity-modulating small molecules, with aims to improve safety and shorten development timelines. The company has secured multibillion-dollar research collaborations with Johnson & Johnson, Bristol Myers Squibb and Blueprint Medicines, with multiple partnered programs progressing toward the clinic and the first expected to enter trials in 2026. (Link)
  4. Vista AI raises $29.5M series B with Cedars-Sinai Health System, Intermountain Health, University of Utah Hospital System, Temple University/Fox Chase Cancer Center, Tampa General Hospital, Khosla Ventures and Bold Brain Capital to Expand Automated MRI Imaging Platform The company’s AI software automates MRI scanning workflows to reduce complexity and variability, helping radiology teams keep up with rising MRI demand amid technologist shortages. Vista AI plans to expand from its FDA-cleared cardiac MRI platform into brain, prostate and spine imaging and add remote scanning services so sites without in-house expertise can offer advanced exams. Early adopters such as Brigham and Women’s Hospital and Radiology Regional report 50% more cardiac MRI slots, elimination of a 28-day backlog, and scan times cut by more than half without adding staff or scanners. (Link)
  5. Converge Bio raises $25M Series A Led by Bessemer Venture Partners with TLV Partners, Saras Capital, Vintage Investment Partners and Executives from Meta, OpenAI and Wiz to Accelerate AI-Driven Drug Discovery The Boston- and Tel Aviv-based startup builds generative AI models trained on DNA, RNA and protein sequences to plug directly into pharma and biotech workflows across target discovery, antibody design, protein yield optimization and biomarker discovery. Its customer-facing systems integrate generative, predictive and physics-based docking models so clients receive ready-to-use platforms rather than stitching tools together. In two years, Converge has completed more than 40 programs with over a dozen customers across the U.S., Canada, Europe and Israel, reporting up to 4–4.5X protein yield gains and single‑nanomolar affinity antibodies, and is now expanding into Asia. (Link)